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Résumé 
Objectif: Évaluer l'efficacité du dépistage de l’hypertension gestationnelle par les 
caractéristiques démographiques maternelles, les biomarqueurs sériques et le Doppler de 
l'artère utérine  au premier et au deuxième trimestre de grossesse. Élaborer des modèles 
prédictifs de l’hypertension gestationnelle fondées sur ces paramètres. 
Methods: Il s'agit d'une étude prospective de cohorte incluant 598 femmes nullipares. Le 
Doppler utérin a été étudié par échographie transabdominale entre 11 +0 à 13 +6 
semaines (1er trimestre) et entre 17 +0 à 21 +6 semaines (2e trimestre). Tous les 
échantillons de sérum pour la mesure de plusieurs biomarqueurs placentaires ont été 
recueillis au 1er trimestre. Les caractéristiques démographiques maternelles ont été 
enregistrées en même temps. Des courbes ROC et les valeurs prédictives ont été utilisés 
pour analyser la puissance prédictive des paramètres ci-dessus. Différentes combinaisons 
et leurs modèles de régression logistique ont été également analysés. 
Résultats: Parmi 598 femmes, on a observé 20 pré-éclampsies (3,3%), 7 pré-éclampsies 
précoces (1,2%), 52 cas d’hypertension gestationnelle (8,7%) , 10 cas d’hypertension 
gestationnelle avant 37 semaines (1,7%). L’index de pulsatilité des artères utérines au 2e 
trimestre est le meilleur prédicteur. En analyse de régression logistique multivariée, la 
meilleure valeur prédictive au 1er et au 2e trimestre a été obtenue pour la prévision de la 
pré-éclampsie précoce. Le dépistage combiné a montré des résultats nettement meilleurs 
comparés avec les paramètres maternels ou Doppler seuls. 
Conclusion: Comme seul marqueur, le Doppler utérin du deuxième trimestre a la 
meilleure prédictive pour l'hypertension, la naissance prématurée et la restriction de 
croissance. La combinaison des caractéristiques démographiques maternelles, des 
biomarqueurs sériques maternels et du Doppler utérin améliore l'efficacité du dépistage, 
en particulier pour la pré-éclampsie nécessitant un accouchement prématuré. 
 
Mot clés: Hypertension gestationnelle, Doppler utérins, Biomarqueurs sériques 
maternels, Caractéristiques démographiques maternelles, Dépistage, Modèle prédictif 
Multivarié. 
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Abstract 
Objective: To evaluate the screening efficacy of maternal demographic characteristics, 
serum biomarkers and uterine artery Doppler (uaD) during the first and the second 
trimester for the hypertensive disorders of pregnancy. To elaborate prediction models of 
these diseases based on the combination of selected maternal demographic 
characteristics, maternal serum biomarkers and uaD indexes.  
Methods: This is a prospective pregnant cohort study of 598 singleton nulliparous 
consecutive women. UaD investigation was performed by transabdominal sonography 
between 11+0 and 13+6 weeks, and between 17+0 and 21+6 weeks. All the serum 
samples for measurement of several placental biomarkers were collected at the first 
trimester. Maternal demographic characteristics were recorded at the same time. Receiver 
operating characteristic curves and predictive values were used to analyze the predictive 
powers of the above parameters. Different combinations and their logistic regression 
predictive models were analyzed.  
Results: Among 598 women, 20 developed preeclampsia (3.3%), 7 developed early-
onset preeclampsia (1.2%), 52 developed gestational hypertension (8.7%), 10 developed 
gestational hypertension with delivery before 37 weeks (1.7%). Second trimester uterine 
artery pulsatility index was the best predictor with statistical significance for all the 
outcomes. In the multivariable logistic regression analysis, the best predictive value in the 
first and second trimester was obtained for the prediction of early onset preeclampsia. 
The combined screening showed significantly better results compared to either maternal 
parameters or Doppler alone. 
Conclusion: As a single marker, second trimester Doppler has the highest predictive 
value for hypertensive disorders, preterm birth and SGA. Combination of the maternal 
demographic characteristics, maternal serum biomarker and uaD improves the screening 
efficacy, especially when this necessitates early delivery.  
 
Key words: Hypertensive disorders of pregnancy, Doppler, Maternal serum biomarkers, 
Maternal demographic characteristics, Screening, Multivariable predictive model.
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Introduction 
With the development of our medical technology and maternal/child care system, 
complications of illegal abortions, infections and death from postpartum haemorrhage are 
seldom seen in recent years. The maternal and perinatal mortality numbers have declined 
dramatically in many countries. However, hypertensive disorder of pregnancy and their 
complications, a major cause of maternal mortality, still complicate approximately 0.34-
11.5% of pregnancies1. These variations depend on age distribution, ethnic differences, 
socioeconomic status, and number of previous deliveries. In addition, hypertensive 
disorders of pregnancy are also found to be strongly associated with fetal growth 
restriction and prematurity, contributing largely to perinatal morbidity and mortality. 2,3 
 
Hypertensive disorders of pregnancy is generally regarded as a multisystem disorder 
specific to pregnant women characterised by widespread endothelial damage which 
originates from the uteroplacental circulation but ultimately involves a variety of other 
organs such as the kidney, liver and brain.  Its pathophysiology remains unclear, despite 
the progress made in the past decades4. Therefore, it is still a challenge to obtain an 
accurate prediction of women who are at risk of developing hypertensive disorders of 
pregnancy.  
 
A theory regarding the etiology of hypertensive disorders of pregnancy has emerged in 
which maladaptation of the vasculature of the uteroplacental unit due to impaired 
trophoblast invasion has been implicated as the main causal factor5. Therefore, it should 
be possible to predict the risk by using Doppler ultrasonography to analyse the 
uteroplacental circulation in the pregnancy. This view is now widely accepted and many 
of these efforts have focused on biochemical markers, primarily those suggesting 
endothelial dysfunction and activation of coagulation6,7. 
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1. Literature review 
1.1. Hypertensive disorders in pregnancy 
1.1.1. Classification of hypertensive disorders in pregnancy 
Many classifications focus on diastolic blood pressure, or changes in diastolic blood 
pressure. Because of the great variation in clinical expression of the syndrome and the 
inability to distinguish symptoms induced by pregnancy from underlying (but often 
latent) maternal disorders, we have difficulty defining the symptoms, the various clinical 
forms, and the pathophysiology that becomes more complex every time new evidence is 
found. In fact, the criteria used to identify the disorder remain a subject of confusion and 
controversy. Obviously, a comprehensive and easily obtainable classification is needed to 
improve prognostics and decision making and to enable comparison of research work. 
 
American College of Obstetricians and Gynecologists (ACOG) has recommended a 
classification to define hypertensive disorders of pregnancy. This classification is widely 
accepted and consists of four terms as follow:8  
• Chronic hypertension  
• Pre-eclampsia / Eclampsia  
• Pre-eclampsia superimposed upon chronic hypertension  
• Gestational hypertension: (1) transient hypertension of pregnancy if pre-eclampsia 
is not present at the time of delivery and blood pressure returns to normal by 12 
weeks postpartum (a retrospective diagnosis) or (2) chronic hypertension if the 
elevation persists. 
1.1.1.1. Definition of chronic hypertension 
Chronic hypertension is defined as hypertension that is present and observable before 
pregnancy or that is diagnosed before the 20th week of gestation. Hypertension is defined 
as a blood pressure equal to or greater than 140 mm Hg systolic or 90 mm Hg diastolic. 
During pregnancy the hypertension remains, but proteinuria does not occur. Women who 
develop hypertension during pregnancy, without proteinuria or seizures, and whose blood 
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pressure remains elevated after pregnancy are also diagnosed with chronic hypertension. 
Hypertension that is diagnosed for the first time during pregnancy and that does not 
resolve postpartum is classified as chronic hypertension too.  
1.1.1.2. Definition of pre-eclampsia/eclampsia 
Pre-eclampsia is characterized by blood pressure greater than or equal to 140 mm Hg 
systolic or 90 mm Hg diastolic occurring after midpregnancy (20 weeks gestation), and 
accompanied by proteinuria. Preeclampsia may be further categorized as mild or severe. 
In the absence of proteinuria the disease is highly suspected when increased blood 
pressure appears accompanied by the symptoms of headache, blurred vision, and 
abdominal pain, or with abnormal laboratory tests, specifically, low platelet counts and 
abnormal liver enzymes. It is recommended that gestational blood pressure elevation be 
defined on the basis of at least two determinations. The repeat blood pressure should be 
performed in a manner that will reduce the likelihood of artifact and/or patient anxiety.  
Proteinuria is defined as the urinary excretion of 0.3 g protein or greater in a 24-hour 
specimen. This will usually correlate with 30 mg/dL ("1+ dipstick") or greater in a 
random urine determination with no evidence of urinary tract infection. However, 
because of the discrepancy between random protein determinations and 24-hour urine 
protein in pre-eclampsia (which may be either higher or lower), it is recommended that 
the diagnosis be based on a 24-hour urine if at all possible or a timed collection corrected 
for creatinine excretion if this is not feasible. Pre-eclampsia always presents potential 
danger to mother and baby. Other conditions may increase blood pressure and even result 
in proteinuria; thus, as the certainty of the diagnosis increases, the requirements for 
careful assessment and consideration for delivery also increase.  
According to the severe of syndrome, ACOG made three categories for pre-eclampsia:  
a. Mild preeclampsia  
 BP 140/90  
 300mg of proteinuria in 24hrs  
b. Severe preeclampsia (any of these)  
 BP 160/110  
 4
 5g of proteinuria in 24hrs  
 Oliguria or <500 ml in 24hrs  
 Cerebral of visual disturbances  
 Pulmonary edema or cyanosis  
 Persistent pain of right-upper quadrant of abdomen 
 Fetal growth restriction  
 Thrombocytopenia (Platelet count is less than 100,000 cells/mm3 and/or evidence 
of microangiopathic hemolytic anemia, with increased lactic 
acid dehydrogenase).  
 Impaired liver function (Elevated hepatic enzymes -alanine aminotransferase 
[ALT] or aspartate aminotransferase [AST]).  
  
c. Eclampsia  
Presence of new-onset seizures in a patient with preeclampsia  
 
1.1.1.3. Definition of pre-eclampsia superimposed upon chronic hypertension  
Lots of evidence indicates that pre-eclampsia may occur in women already hypertensive 
(i.e., who have chronic hypertension) and that the prognosis for mother and fetus is much 
worse than with either condition alone. Skills are needed to distinguish superimposed pre-
eclampsia from worsening chronic hypertension.  The principle of high sensitivity and 
unavoidable overdiagnosis is appropriate in order to facilitate clinical management. Close 
observation, with delivery indicated by the overall assessment of maternal-fetal well-
being shall be provided at suspicion of superimposed pre-eclampsia. The diagnosis of 
superimposed pre-eclampsia is highly likely associated with the following findings:  
• In women with hypertension and no proteinuria early in pregnancy (<20 weeks), 
new-onset proteinuria, defined as the urinary excretion of 0.3 g protein or greater in 
a 24-hour specimen.  
• In women with hypertension and proteinuria before 20 weeks' gestation.  
• Sudden increase in proteinuria.  
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• A sudden increase in blood pressure in a woman whose hypertension has previously 
been well controlled.  
• Thrombocytopenia (platelet count <100,000 cells/mm3).  
• An increase in ALT or AST to abnormal levels. 
1.1.1.4. Definition of gestational hypertension (GH)  
The woman who has blood pressure elevation detected for the first time after 20 weeks of 
gestation, without proteinuria, is classified as having gestational hypertension. This 
nonspecific term includes women with the pre-eclampsia syndrome who have not yet 
manifested proteinuria as well as women who do not have the syndrome. The 
hypertension may be accompanied by other signs of the syndrome, which will influence 
management. The final differentiation that the woman does not have the pre-eclampsia 
syndrome is made only postpartum. If pre-eclampsia has not developed and blood 
pressure has returned to normal by 12 weeks postpartum, the diagnosis of transient 
hypertension of pregnancy can be assigned. If blood pressure elevation persists, the 
woman is diagnosed as having chronic hypertension. Note that the diagnosis of 
gestational hypertension is used during pregnancy only until a more specific diagnosis 
can be assigned postpartum. 
It is the elevation of blood pressure (>140/90mm Hg) during pregnancy or in the first 24 
hours postpartum without other signs of preeclampsia or preexisting hypertension. The 
hypertension usually resolves in days to weeks after delivery. Rarely, women will 
become persistently hypertensive following a pregnancy complicated by transient 
hypertension. This condition is thought to foreshadow the development of essential 
hypertension later in life.  
1.2. Measurement of blood pressure 
For the purposes of accuracy and standardization, health professionals should take blood 
pressure measurements in pregnant women with the patient seated rather than lying on 
her side, because substantial differences exist between the blood pressures in the upper 
and lower arms when the patient is lying on her side. In addition, the National Institutes 
of Health (NIH) recommends that the diastolic pressure reading should be taken at 
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Korotkoff 5, with the disappearance of sound—not at Korotkoff 4, when sound becomes 
muffled. To meet strict criteria for hypertension, the patient's readings must be elevated 
on at least two separate occasions at least six hours apart. 
a. Mercury manometer is still the gold standard. 
b. Comfortable sitting position, patient seated with feet supported for 2-3 minutes, 
arm at the level of the heart. 
c. Use appropriately sized cuff (large cuff if arm circumference > 33 cm). 
d. Record systolic and diastolic pressures, the latter as Korotkoff Vth 
(disappearance).  Only use Korotkoff IVth when Korotkoff Vth is absent. 
e. If  the Korotkoff Vth sound is not present, use the Korotkoff IVth but should note 
as such  
f. In serial readings use the higher set of values  
g. Relative BP change of 30mmHg/15mmHg is no longer used as hypertension 
 
1.3. Epidemiology 
1.3.1. Prevalence 
The overall prevalence of hypertensive disorders of pregnancy was 7.5% in Brazilian 
women9, 6.4% in African American, 4.8% in other American women10, 3.7% in the 
United States11, 3.3 % in southern Iran12, 3% in northwest Saudi Arabia 13 and  2.6% in 
southwest Saudi Arabia14. These figures may not be accurate because the information is 
usually based on hospital populations and therefore biased, especially in countries where 
access to health care is low. The differences in classification and definitions also 
contribute to the variation of these figures, which may be different even among reports 
from the same region. 
 
1.3.2. Impact on maternal and fetal mortality 
Research shows that the occurrence of hypertensive disorders of pregnancy is inversely 
related to assess to health care of that region. In developed countries, hypertensive 
disorders of pregnancy were responsible for 16.1% (6.7-24.3%) of all maternal deaths. 
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The number was much higher (25.7%, 7.9-52.4%) in developing countries, especially in 
Latin America and the Caribbean. 15 (Fig. 1) 
 
Fetal mortality from preeclampsia was usually caused by associated prematurity, IUGR, 
or hypermagnesemia. Hypertension and the poor placentation often seen with 
preeclampsia may result in placental insufficiency and eventually IUGR which is 
associated with several problems, including fetal and neonatal hypoxemia, acidosis and 
newborn resuscitation.  
 
Svein Rasmussen and Lorentz M Irgens’s study on 223541 single births in Norway from 
1999 to 2002 showed that mothers with severe preeclampsia or preeclampsia 
superimposed on chronic hypertension gave birth earlier than those who had mild 
preeclampsia or transient hypertension. Median gestational age at birth in transient 
hypertension, mild-, and severe preeclampsia were 279, 277, and 259 days, respectively, 
against 280 days in normotensive pregnancies, while those with chronic hypertension 
with and without preeclampsia had median gestational age of 268 and 279 days, 
respectively. The rates of preterm birth (less than 37 weeks of gestation) in transient 
hypertension, mild-, and severe preeclampsia were 8.1, 9.7, and 48.2%, respectively, 
against 5.0% in normotensive women. The rates were also significantly higher in chronic 
hypertension with or without preeclampsia(34.5% and 8.9%).16 (Fig. 2)  
 
Victoria M Allen and their colleagues performed a study on all pregnant women and 
births in the Canadian province of Nova Scotia between 1988 and 2000, including 
135,466 pregnancies. In their study, after controlling for potential confounders, women 
with any hypertensive disorder were 1.4 (95% CI 1.1, 1.8, P = .02) times more likely to 
have a stillbirth and 1.8 (95% CI 1.7, 1.9, P < .001) times more likely to have SGA as 
compared with normotensive women. Women with pre-existing hypertension were 3.2 
(95% CI 1.9, 5.4, P < .001) times more likely to have a stillbirth and 2.5 (95% CI 2.1, 
2.9, P < .001)times more likely to have SGA  as compared with normotensive women.17 
(Table 1) 
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1.4. Risk factors of hypertensive disorders of pregnancy  
Incidence of hypertensive disorders of pregnancy is associated with a number of risk 
factors (Table 2). Based on these factors, a comprehensive medical history and physical 
examination at the first antenatal visit can be used to estimate a mother’s risk of 
developing the disorder.  
Risk factors can be divided into four major groups as follows: 
1.Pregnancy associated risk factors 
2.Chronic risk factors 
3.Hereditary risk factors 
4.Other risk factors 
 
Section 1.4.1.-1.4.4. provide detail descriptions of each of these risk factors. 
 
1.4.1. Pregnancy associated risk factors 
1.4.1.1. Nulliparity 
Women in their first pregnancy are at an increased risk of hypertensive disorders of 
pregnancy. Previous pregnancies appear to have a protective effect, even if they ended 
early in abortion. In contrast, women with a history of hypertensive disorders in previous 
pregnancies are at an increased risk.18 It is likely that women who have recurrent pre-
eclampsia have an underlying pathological phenotype that puts them at risk of 
hypertension.19 
 
1.4.1.2. High-risk pregnancy, abnormal pregnancy 
Factors associated with the pregnant state itself that increase the risk of hypertensive 
disease are twin pregnancy20,  polyhydramnion21, hydatidiform molar pregnancies and 
hydrops fetalis.4  Extremely young (teenage) or relatively old (over 35) women are at an 
elevated risk too.22 
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1.4.1.3. Sperm exposure and time interval between deliveries 
Normal pregnancy requires adaptation of the maternal immune response, so that the 
foetus and placenta, being partly allogenic, are not rejected. In pre-eclampsia, this 
adaptation may be inadequate in a first pregnancy with a new partner (and limited sperm 
exposure, primipaternity theory); while in subsequent pregnancies with the same partner 
the risk is lower.23-25 
Although numerous studies have shown an increased risk of pre-eclampsia associated 
with a new partner26, some investigators challenged this theory. In Trogstad’s study on 
547 238 women, time interval between pregnancies have shown a significant impact on 
the risk of pre-eclampsia. They also found that a change of paternity for the second 
pregnancy was associated with a reduced risk of pre-eclampsia after controlling for the 
time since first delivery, but the interaction between change in paternity and time between 
deliveries was significant only for women with no previous pre-eclampsia (P = 0.04) and 
the interaction between history of pre-eclampsia and time interval between the two 
deliveries was highly significant (P < 0.001). For women with no previous pre-eclampsia 
the risk of pre-eclampsia in second pregnancy increased with increasing time interval, 
whereas for women with previous pre-eclampsia the risk tended to decrease with 
increasing time interval between deliveries.27 
 
The increased incidence of pre-eclampsia in donor insemination pregnancies indicates 
that prolonged exposure to paternal spermatozoa prior to conception, as in the partner 
insemination group, reduces the risk. Since recipients of donated spermatozoa are 
exposed to foreign fetal antigens encoded by the paternally derived genes, they are at 
higher risk. The finding of an increased incidence of gestational hypertension in ovum 
donation pregnancies provides further support to the hypothesis that the development of 
pre-eclampsia may be due to altered or inadequate immunoprotection of the fetoplacental 
unit in oocyte recipients due to short duration of exposure to non-maternal antigens.28 
 
 
1.4.2. Chronic risk factors 
Research indicates that some chronic diseases are associated with hypertensive disorders 
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of pregnancy, as detailed in the following paragraphs. 
1.4.2.1. Cardiovascular disorders 
Preeclampsia and cardiovascular disorders share similar risk factors like obesity, 
hyperlipidemia, increased insulin resistance, and analogous pathophysiology such as 
increased oxidative stress and vascular injury. 29  Cardiovascular disorders are risk factors 
for hypertensive disorders of pregnancy. Unfavourable cardiovascular and metabolic 
profiles may represent primary causes of pre-eclampsia, as well as subsequent 
cardiovascular disease.19 
1.4.2.2. Chronic hypertension 
Pregnancy has detrimental effects on chronic hypertension. The probability of 
exacerbating of hypertension and development of preeclampsia and eclampsia in patients 
with chronic hypertension is much higher than previously normotensive population.30 
1.4.2.3. Renal diseases 
Women suffering from renal disease have a high risk too, because hyperuricaemia 
precedes significant proteinuria in pre-eclampsia and is thought to result from either 
enhanced tubular reabsorption of uric acid, or breakdown of nuclear (or therefore purine) 
rich syncytiotrophoblast.31 
1.4.2.4. Obesity 
Obese women and those with hypercholesterolemia have an increased risk of developing 
or having preexisting manifestations of the metabolic syndrome. So, there are lots of 
potential risk factors to develop this disease.32  
1.4.2.5. Diabetes 
Diabetes is a condition in which the body cannot use the sugars and starches 
(carbohydrates) it takes in as food to make energy. The body either makes too little 
insulin in the pancreas or cannot use the insulin it makes to change those sugars and 
starches into energy. As a result, the body collects extra sugar in the blood and gets rid of 
some sugar in the urine. The extra sugar in the blood can damage organs of the body, 
such as the heart, eyes, and kidneys, if it is allowed to collect in the body too long. And, 
 11
insulin resistance might affect the pathogenesis of hypertensive disorders in pregnancy 
since mid-trimester. Women with hypertensive disorders in pregnancy were more likely 
to have gestational diabetes and pre-existing diabetes compared with normotensive 
women (2.3% and 0.3%, respectively). 17 
1.4.2.6. Smoking 
An interesting observation is that smoking appears to have a protective effect. Women  
with a smoking history, even though they quit smoking in early pregnancy, still 
demonstrate lower probability of  developing hypertensive disorders in pregnancy33 
 
1.4.3. Hereditary risk factors 
Research indicates that women with positive family history have a higher risk of 
developing preeclampsia. They may have inherent abnormalities, which predispose to 
vascular disease.34 And, some ethnic groups, like African-American and Hispanic women 
in the US, have a higher incidence of hypertensive disorders of pregnancy compared to 
white women.35 Some investigators believe that the hypothesis of a single gene whose 
expression is pregnancy-specific and which is alone responsible for the progression from 
preeclampsia to eclampsia. Various candidate genes have been proposed. Arngrimsson 
and colleagues have reported the highest lod score for a region on 2p13 without any 
obvious candidate genes, which seems has been confirmed.36,37  But, in fact, no gene has 
gained common acceptance as the one that causes the hereditary component of 
preeclampsia. 
 
1.4.4. Other risk factors 
Stress and work related psychosocial strain increase the risk of developing hypertensive 
disorders of pregnancy. One possibility suggested that stress contributes to the etiology of 
preeclampsia via priming the immune system to produce inflammatory cytokines. 38 On 
the other hand, Annelies Rep’s study mentioned that severe hypertensive disorders of 
pregnancy have a high psychological impact, especially when gestational age at onset of 
disease is below 30 weeks or if adverse infant outcome occurs.39 
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1.5. Doppler analysis and hypertensive disorders of pregnancy 
1.5.1. Pathophysiology of hypertensive disorders of pregnancy 
Blood supply to uterus is mainly provided by the left and right uterine arteries and to a 
less extent by the ovarian arteries. In the parametrium, the uterine arteries branches into 
the arcuate artery which in turn branch into the radial arteries. After crossing the 
myometrium, these radial arteries issued spiral arteries at the junction of the myometrial-
endometrial and terminate in the basal endometrium. Radial artery also issue branches 
named basal arteries which do not pass endometrium. 
1.5.1.1. Normal adaptation of the uteroplacental vasculature in pregnancy 
In the first few weeks of pregnancy, conceptus cytotrophoblast cells invade the basal 
decidua and the decidual portion of the spiral arteries.  Cytotrophoblast is divided into 
two different types at this stage. One is called endovascular trophoblast. The other is 
called interstitial trophoblast which penetrates the basal deciduas. 
The interstitial trophoblast migrates retrogradely to colonise the myometrium at 10 to 12 
weeks of pregnancy. Between 12 to 16 gestational weeks, endovascular trophoblast 
invades the myometrial portions of the spiral arteries, replaces the endothelium and 
disrupts the muscular vessel wall.  
Finally, distended fibrinoid tubes incapable of vasoconstriction replace the spiral arteries 
from the myometrium to the intervillous space. This results in a low-resistance, high-
capacity vascular circulatory system which facilities adequate maternal blood supply to 
the growing fetus. 
1.5.1.2. Uterine vascular pathology in hypertensive disorders of pregnancy 
Since the 1950s it has been acknowledged that hypertensive disorders of pregnancy were 
associated with extensive placental infarction. Thanks to increasing knowledge of the 
normal physiological adaptation of the arteries of the placental bed and more 
sophisticated microscopic techniques in recent days, people have better understanding of 
the pathogenesis of hypertensive disorders of pregnancy with two major distinct 
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abnormalities found in the uteroplacental circulation. First, normal physiological 
adaptation of pregnancy is impaired or absent in hypertensive disorders of pregnancy. 
Second, a distinctive vaso-occlusive lesion termed "acute atherosis" was found. These 
abnormalities impair maternal blood flow which results in placental insufficiency during 
pregnancy. 
 
a. Impaired physiological adaptation:  
Physiological changes of uterine artery only exist at the endometrial segments of the 
spiral arteries while the myometrial segments remain unchanged. Besides, trophoblast 
cells do not exist in the vessel wall of the spiral arteries that failed to undergo 
physiological changes. The extent of endovascular trophoblast invasion and physiological 
changes varies between spiral arteries. Some arteries do not show any physiological 
changes along their entire length.40,41 
 
The association between impaired adaptation of spiral arteries, hypertensive disorders of 
pregnancy, and fetal growth restriction has been confirmed in recent studies.42,43  The 
studies also show that endovascular trophoblast invasion is not an all-or-none 
phenomenon and that there is a gradient in the extent of trophoblast invasion of decidual 
and myometrial arteries in both normal pregnancy and pre-eclampsia. Uteroplacental 
vascular pathology, although being present in a percentage of normal pregnancies, has 
also been related to spontaneous prematurity and placental abruption. 44  
 
b.  Acute atherosis:   
Research shows that acute atherosis is related to pre-eclampsia and fetal growth 
restriction. An atheromatous infiltrate consisting of lipid-laden "foam cells" is a typical 
lesion characteristics, which originated from myocytes or macrophages, fibrin, and 
mononuclear cells. In addition, there is large amount of fibrin deposited in the vascular 
endothelium and the media. Cellulose necrosis and macrophage infiltration appeared at 
the earlier stages of the lesions.45  
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It was believed that acute atherosis only occurs in spiral arteries which fail to undergo 
physiological changes. Latest research showed that it can also occur in physiologically 
adapted spiral arteries.45,46 
 
It is not clear what causes impaired trophoblast invasion and acute atherosis. The fact that 
trophoblast cells do not exist in the vessel wall of unchanged spiral arteries suggests a 
specific defect in the invasion of the endovascular type of trophoblast.  The failure of 
endovascular trophoblast to express vascular adhesion phenotype molecules could play a 
role by impairing adhesion to the vessel wall. In recent studies, an increased number of 
activated macrophages were found in the placental bed of patients with pre-clampsia and 
widespread apoptosis of placental cytotrophoblast cells.47,48 This phenomenon could be 
caused by a maternal immunological response against endovascular trophoblast, perhaps 
triggered by the deficiency in the expression of vascular adhesion molecules. In addition, 
recent reports indicate that a deficiency of angiogenic growth factors such as vascular 
endothelial growth factor (VEGF) and placental growth factor (PIGF) is associated with 
pre-eclampsia.49,50  Further investigation is required to understand the precise meaning of 
these findings. 
 
1.5.2. Principles of Doppler analysis of ulteroplacental blood flow 
Doppler signals from the maternal side of the uteroplacental circulation can be derived 
from the uterine artery, the arcuate arteries, or the spiral arteries (Fig. 3). 
These vessels undergo profound changes in early pregnancy resulting in increased 
volume flow. 
Cytotrophoblastic invasion of the maternal spiral arteries and replacement of their 
endothelium is central to the successful outcome of pregnancy, and results in the 
establishment of a low-resistance high-flow uteroplacental circulation. This process, 
known as physiologic transformation, begins as early as the 10th day after conception and 
continues throughout the pregnancy. 
The noninvasive assessment of uterine artery resistance by means of Doppler ultrasound 
has demonstrated that a high-resistance blood flow pattern is invariably present at the 
beginning of the pregnancy. As a result of the physiological transformation of the spiral 
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arteries, a low-resistance pattern develops at varying gestational ages in different 
individual pregnancies.42 
 The mature placenta is a low resistance, high capacity system in which arteries have lost 
their elastic wall and drain directly into large venous pools without an interposed 
capillary bed. This results in low systolic maximum velocity and high forward diastolic 
flow. These changes are completed in normal pregnancy between 20 and 24 weeks (Fig.4) 
1.5.3.  The Doppler indices 
Several indices have been described to quantify the information from the Doppler 
waveform. (Fig. 5)  
The Resistance Index (RI) was introduced in 1974 by Planiol.51 The Pulsatility Index (PI), 
a modified version of the resistance index, was introduced in 1971 by Gosling RG.52 
The systolic/diastolic ratio is also used frequently in clinical practice. Several authors 
have noticed the presence of a diastolic “notch”(Fig.6) in waveforms from the 
uteroplacental circulation and used it in the prediction of pregnancy complications. This 
"notch" is present in most waveforms in nonpregnant women and early pregnancy but 
disappears in the second trimester in normal pregnancy. The presence of a diastolic notch 
beyond the 22nd week is generally considered to be abnormal. The physiological 
background of the changes in uteroplacental flow velocity waveform (FVW)s has been 
investigated using computer models to simulate the uteroplacental circulation.  
To obtain reliable information about the uteroplacental circulation, the uterine artery is 
the best sample site; it is easy to locate on real time imaging, provides good 
reproducibility, and reflects the resistance in the entire distal placental bed. 53,54 
 
1.5.4. Prediction of hypertensive disorders of pregnancy by Doppler 
ultrasound  
1.5.4.1. Doppler ultrasound as a diagnostic and prognostic tool in complicated 
pregnancies 
Doppler ultrasound of the uteroplacental circulation could be used to predict poor 
pregnancy outcome in hypertensive pregnancies. In 1983, Campbell et al. used a pulsed 
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Doppler system to detect abnormal flow velocity waveforms (FVWs) in the arcuate 
arteries of 31 women with hypertension or suspected FGR, and found that abnormal 
FVWs were associated with a higher risk of proteinuric hypertension, premature delivery, 
and low birthweight. In addition, women with normal FVWs were likely to have a normal 
pregnancy outcome.55 
1.5.4.2. Doppler analysis of the uteroplacental circulation as a screening test for 
pregnancy complications 
The recognition of abnormal uteroplacental FVWs in patients with hypertensive disorders 
of pregnancy suggests the possibility of a screening test in early pregnancy. It is widely 
believed that in case of hypertensive disorders of pregnancy, uteroplacental resistance is 
increased already in the beginning of the second trimester, when normal adaptation of the 
spiral arteries has failed to occur. In 1986, Campbell and his colleagues performed the 
first screening study. In their study, a pulsed Doppler apparatus was used to assess the 
blood flow velocity profiles in uterine vessels (arcuate arteries) at 16 to 18 weeks' 
gestation. 56 Their purpose is to determine if complications associated with impaired 
trophoblastic invasion of the placental bed (ie, pregnancy-induced hypertension, 
intrauterine growth retardation, and fetal asphyxia) could be predicted by this 
measurement. Thirty-one of 126 consecutive pregnancies developed one or more of the 
above complications. The sensitivity was 68% and the specificity 69%; the predictive 
value of a positive test was 42% and that of a negative test 87%.  
 
Presently, more and more investigators use Doppler as a screening test, and found that 
there are several points worth of attention.  
 
a. The gestational age at the time of measurement  
• First trimester 
In normal pregnancy, uteroplacental resistance falls gradually between the late first 
trimester and mid second trimester. Screening before 20 weeks might result in a false-
positive test result in subjects in which spiral artery adaptation is in normal progress but 
not yet completed. 57,58 
• Second trimester 
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Good predictive values are reported in studies where an initial scan at 18-20 weeks is 
followed –if abnormal- by a repeat scan at 24 weeks.59 Two-stage screening (repeating an 
abnormal test after 4 weeks) have better predictive result in comparison with single 
sampling.60 
 
b.  Doppler screening is more accurate in predicting proteinuric pre-eclampsia 
compared to pregnancy-induced hypertension.  
Some investigators found that abnormal uterine Dopplers have better predictive values 
for subgroups such as “severe” pre-eclampsia, in comparison to "uncomplicated" 
pregnancy-induced hypertension and pre-eclampsia.7,61, 62 In their studies, “severe” pre-
eclampsia includes the following symptoms: diastolic blood pressure over 90 mmHg, 
severe proteinuria, pre-eclampsia requiring delivery before 34 weeks, and pre-eclampsia 
combined with SGA (≤ the 5th centile, ≤ the 10th centile).  
 
c. The location of the placenta:  
Lower PI and RI values are found in the uterine artery on the placental side at 16-20 
weeks. In pregnancies with unilateral placental location, the uteroplacental Doppler flow 
measurements show significant side-to-side differences. In strictly unilateral placentas, 
there is a greater incidence of abnormal FVWs compared to central placentas and a 
greater incidence of pregnancy complications. Gonser’s study suggests that a laterally 
located placenta is associated with a significantly increased incidence of preeclampsia, 
with a risk ratio of 3.1 when compared to pregnancies with centrally located placentas.63 
 
d. The persistence of PI and Notch: 
Gomez found that the persistence of an abnormal mean PI from the first to the second 
trimester identified the group with the greatest risk for adverse perinatal outcome (OR, 
10.7; 95% CI, 3.7-30.9). In addition, women in whom the uterine artery mean PI shifted 
from abnormal to normal between the two trimesters and women in whom the reverse 
shift occurred showed a similar intermediate risk (OR, 5; 95% CI, 2.1-10.6), comparable 
to that in women with persistence of a bilateral notch (OR, 5.6; 95% CI, 2.9-10.7).64  
And, the high prevalence of notching indicates that the high mean uterine artery index is 
a more reproducible and objective basis for screening than using bilateral notches alone.62  
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1.6. Serum markers and hypertensive disorders of pregnancy 
 
Early placental abnormalities were targeted by most current hypotheses regarding the 
pathophysiologic mechanisms of pregnancy-induced hypertention. Human placenta 
synthesizes steroid, protein, and glycoprotein hormones throughout gestation. A large 
number of serum markers that are measured in the maternal circulation have been 
evaluated in the prediction of hypertensive disorders of pregnancy. These include tests of 
fetal and placental endocrinology dysfunction, maternal renal dysfunction, endothelial 
dysfunction, and markers of abnormal oxidative stress. 65 It is becoming more and more 
evident that circulating factors in the maternal circulation may be associated with or 
cause defective trophoblastic invasion. 
 
1.6.1. Human Chorionic Gonadotropin (hCG) 
The hormone human chorionic gonadotropin (hCG) is a glycoprotein produced by 
syncytiotrophoblasts of the placenta. It is a peptide hormone produced in pregnancy, that 
is made by the embryo soon after conception and later by the syncytiotrophoblast. Its role 
is to prevent the disintegration of the corpus luteum of the ovary and thereby maintain 
progesterone production that is critical for a pregnancy in humans. The production of 
hCG by the placenta in early pregnancy is critical for implantation and maintanance of 
the blastocyst. hCG interacts with the LHCG receptor and promotes the maintenance of 
the corpus luteum during the beginning of pregnancy causing it to secrete the hormone 
progesterone.66  Progesterone enriches the uterus with a thick lining of blood vessels and 
capillaries so that it can sustain the growing fetus. Due to its highly negative charge hCG 
may repel the immune cells of the mother, protecting the fetus during the first trimester. It 
has also been hypothesized that hCG may be a placental link for the development of local 
maternal immunotolerance.67 
 
As preeclampsia is characterized by disturbed trophoblastic physiology, early placental 
dysfunction could be reflected by altered hCG concentrations. 
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Smith et al. reported increasing hCG Levels in severe preeclampsia for the first time in 
193468. Since then numerous studies have suggested that elevated maternal hCG serum 
levels may be associated with preeclampsia. 69-71 
1.6.2. Inhibin  A 
Inhibin is a peptide that is an inhibitor of Follicle-stimulating hormone (FSH) synthesis 
and secretion. Inhibin contains an alpha and beta subunit linked by disulfide bonds. Two 
forms of inhibin differ in their beta subunits (A or B), while their alpha subunits are 
identical. In women, FSH stimulates the secretion of inhibin from the granulosa cells of 
the ovarian follicles in ovary. In turn, inhibin suppresses FSH.  
Inhibin A is glycoprotein hormone and member of the transforming growth factor b 
family. In pregnancy, it is predominantly secreted by the placenta. In normal pregnancies, 
its serum concentration rise during the third trimester. In vitro studies suggested that 
inhibin A increases human chorionic gonadotrophin (HCG) secretion,72 whereas, in turn, 
HCG stimulates the production of inhibin A.73 This causal chain might explain the 
generally observed simultaneous increase of inhibin A. 
On the other hand, there is partial or complete failure of trophoblastic invasion of the 
myometrial segments of the spiral arteries for preeclampsia. The failure of trophoblastic 
invasion is associated with ischaemic damage to the syncytiotrophoblast causing 
functional alteration of the surface layer of the syncytiotrophoblast. This alteration in the 
surface layer of the syncytiotrophoblast has been postulated as a contributory factor for 
the increased ‘leakage’ of inhibin A into the maternal circulation, which might explain 
the increase in concentration of maternal serum inhibin A in preeclampsia.74 
1.6.3. Pregnancy-associated plasma protein A (PAPP-A) 
Pregnancy-associated plasma protein A (PAPP-A) is an important pregnancy protein. The 
main site of PAPP-A synthesis during pregnancy is the placenta. In the women the levels 
of PAPP-A are highest during pregnancy, when plasma levels increase by a factor of 
about 150 as compared to the nonpregnant state. PAPP-A is most abundant in the 
peripheral maternal circulation. It cleaves the insulin-like growth factor-dependent 
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binding protein-4 (IGFBP-4) and consequently modulates the amount of bioactive IGF-2, 
a factor known to promote trophoblast invasion.  
 
Fournier’s study suggested that PAPP-A, which can be localized in the trophoblast and in 
the deciduas, might be considered as an early marker of physiological trophoblast 
invasion.75 Since trophoblast is a source of PAPP-A in vivo, PAPP-A has been used in 
prenatal genetic screening and studies of atherosclerosis.76,77 Low blood levels of PAPP-
A at first trimester of gestation suggest an increased risk of intrauterine growth 
restriction,78 trisomy 2179, premature delivery,80 preeclampsia,81 and stillbirth.82  
1.6.4. A disintegrin and metalloprotease (ADAM12) 
ADAM12 is a recently discovered pregnancy associated member of the ADAM family. 
ADAM12 is an IGFBP-3 and IGFBP-5 protease and is present in human pregnancy 
serum. The ADAMs constitute a multi-domain glycoprotein family with proteolytic and 
cell-adhesion activities. 83,84  Human ADAM12 exists in two forms, ADAM12-L (long) 
and ADAM12-S (short), the latter being the secreted form of ADAM12. ADAM12-S 
differs from ADAM12-L at the C-terminal end in that it does not contain the 
transmembrane and cytoplasmatic domains. The mRNA for ADAM12-S is particularly 
abundant in placenta.85 
Laigaard’s study indicates that serum ADAM12 levels in women who developed pre-
eclampsia during pregnancy had a mean log MoM which was significantly lower than the 
mean log MoM for ADAM12 levels observed in serum samples from women with 
normal pregnancy (P < .008). They suggested that the IGF axis may play a role in 
preeclampsia. ADAM12 may be a useful early marker for preeclampsia.86 
1.6.5.  Maternal serum placental protein 13 (PP13) 
First isolated from human placenta and characterized in 1983,87 Placental protein 13 
(PP13) is a 32-kd dimer protein that is produced only in the placenta and is thought to be 
involved in normal implantation and maternal artery remodeling.  It is the member of the 
so-called ‘pregnancy –related protein’ family, which  consists of 56 different proteins 
diverging either in their structure or function and grouped earlier on the basis of their 
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increased expression in placenta, in some maternal tissues, especially in the liver or in the 
fetus during pregnancy.88 
As a potential marker for early detection of PE in low risk groups, PP13 has been 
designated galectin-13 because of its homology with members of the galectin family. 
There is a single conserved carbohydrate recognition domain and a strong binding 
affinity to sugar residues widely expressed in the placenta.89 It was suggested that the 
unique dimerization via disulphide bonds might affect the activity of PP13upon the 
oxygenization changes in the placenta. As other galectins are involved in 
immunobiological functions, PP13 and its placental homologues might also have immune 
functions at feto-maternal interfaces. 89 
Recent tests of  PP13 in pregnancy serum during the 1st and 2nd trimesters showed a 
decreased PP13 concentration in patients later developing pre-eclampsia , IUGR and 
PTD, 90-92 as well as a stably increased PP13 serum value during normal pregnancy 
period. 
 
 
1.7. Screening test for hypertensive disorders of pregnancy 
1.7.1. Serum Biomarkers screening test for hypertensive disorders of 
pregnancy 
Risk prediction for pregnancy hypertensive disorders is of great value. Early tests focused 
on detecting early manifestations of disease, such as hypertension, proteinuria, edema, 
excessive weight gain, and increased vascular resistance. Based on the test result, 
clinicians identify women who require closer surveillance and permit early referral for 
their treatment when signs or symptoms occur. More recently, investigators are looking 
for changes closer to the period when the pathogenic events leading to preeclampsia 
occur, searching for measurable manifestations of the abnormal placentation and reduced 
placental perfusion that is said to initiate this disorder. Many of these efforts have focused 
on biochemical markers, primarily those suggesting endothelial dysfunction and 
activation of coagulation. 
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1.7.1.1. Single maternal biomarker screening test 
There are differences in the metabolism of women who subsequently develop 
hypertensive disorders of pregnancy compared with women who remain normotensive 
during their pregnancy, as indicated by the serum biochemical assays. 
Large amount of research has been done trying to identify a unique biomarker screening 
test that would predict the risk of developing hypertensive disorders of pregnancy before 
the classic symptoms appear. These include tests of the dysfunction of fetal and placental 
endocrinology, of maternal renal dysfunction, endothelial dysfunction, and markers of 
abnormal oxidative stress. 65 Only modest correlations were observed in most of these 
studies. The low predictive values could not justify any of them as a screening test alone 
for this condition.93,94 
1.7.1.2. Combinations of maternal biochemical markers test 
To be used in a screening program covering all pregnant women indiscriminately, the test 
should combine a high sensitivity to justify the cost. It should also have a high positive 
predictive value so as to avoid unnecessary interventions.65 No a single biomarkers 
screening test available today can meet these requirements. 
The use of more maternal biomarkers in screening program has much better predictive 
power.95 It could be used to identify among high-risk pregnant women those with a very 
low probability of developing preeclampsia in their present pregnancy. In Floro’s study,  
activin A, inhibin A, and  a combination of activin A and inhibin A were tested 
respectively in a high risk population, and the test result showed that combining both 
hormones improved the predictive value of the test (positive predictive value of 86%  as 
compared to 55% with activin A alone and 70% with inhibin A alone )96 In this case, a 
multi-biomarkers test that achieves optimal negative predictor value could be used to 
reduce anxiety in the patient and to prevent unnecessary intervention and hospitalization. 
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1.7.2. Combinations of maternal factors, maternal biochemical markers 
and uterine artery Doppler test 
It is widely accepted that the etiology of preeclampsia is multifactorial. They detect the 
early placental changes that are part of the evolving disease and only predict the 
imminent development of the preeclampsia syndrome. This explains why screening in the 
first trimester is unlikely to work as well as in the second or third trimester. 
The use of multiple markers in the screening reflects different aspects of the disease 
process and increases the specificity and sensitivity of the screening. Combinations of 
maternal factors, maternal biochemical markers and uterine artery Doppler improve the 
screening efficacy for prediction of hypertensive disorders of pregnancy, especially for 
preeclampsia. 
1.7.2.1. First trimester screening 
One effective way of screening women in the second trimester is to use Doppler 
ultrasonography to assess increased impedance of blood flow in the maternal uterine 
arteries. However, the performance of this method became much poorer when 
investigated in the first trimester. In Martin’s study, their Doppler index only showed 
27% sensitivity for identifying pre-eclampsia in an unselected population at 11-14 
weeks.97 
One suggestion was to combine uterine artery Doppler with serum markers. This 
combination improves the effectiveness of the screening and has a relatively high 
detection rate. It also helps identify patients amenable to effective prevention early 
enough.98 
 
Plasencia proposed a screening method in which maternal characteristics (such as 
maternal age, ethnic origin, BMI, smoking status and medical and obstetric history), free 
β-hCG and PAPP-A, as well as uterine artery Doppler were combined together. This 
screening method appeared to be particularly effective in identifying women who develop 
severe early onset PE (Pre-eclampsia/toxemia) rather than late-onset disease, GH or SGA. 
For a false-positive rate of 10%, the predicted detection rate of PE requiring delivery 
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before 34 weeks was 82%, compared to 31% for late PET, 12% for GH and 18% for 
SGA.61 
1.7.2.2. Second trimester screening 
Doppler is an effective method for screening early onset PE. Combining uterine artery 
Doppler velocimetry around 22 weeks’ gestation with maternal biochemical markers 
further improves the sensitivity of the PE screening method.99 As shown in Aquilina’s 
study, for pre-eclampsia requiring delivery before 37 weeks, the sensitivity improved 
from 27% to 60% and the positive likelihood ratio improved from 9.2 to 20.8 at a false-
positive rate of 3%  when uterine artery notch data was combined with inhibin-A. The 
improvement in sensitivity was statistically significant for both preeclampsia (P < 0.05) 
and preterm pre-eclampsia (P < 0.02) when compared to either inhibin-A or uterine artery 
Dopplers alone.100 
1.7.2.3. First trimester maternal serum markers in combination with second trimester 
uterine artery Doppler screening 
The underlying pathology of hypertensive disorders of pregnancy is present at the early 
stages of pregnancy. There is evidence that it is associated with impaired placentation, 
which may produce unknown substance(s) leading to endothelial dysfunction. A variety 
of placental proteins and hormones have been studied as potential early markers of pre-
eclampsia.  
The use of Doppler ultrasonography to assess increased impedance to blood flow in the 
maternal uterine arteries is an effective method of screening women in the second 
trimester. 
Therefore, the use of abnormal levels of first trimester biomarkers for selecting women 
for further follow-up with uterine artery Doppler may further improve the clinical 
discrimination.101 
Spencer’s study showed that both PP-13 and PAPP-A, when coupled with second-
trimester mean PI as measured by Doppler velocimetry, provide better prediction over the 
use of Doppler ultrasonography alone. With a specificity set to 0.80, they got sensitivity 
for early onset preeclampsia and late onset preeclampsia 0.70 and 0.73 respectively. 81 
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2. Thesis project 
2.1. Viewpoints and objectives for the current study 
Prevention of hypertensive disorders of pregnancy is a big challenge in clinic research. 
During the past 2 decades, numerous clinical studies and randomized trials were reported. 
These reports described the use of various methods to reduce the incidence and severity 
of preeclampsia. Prevention of any disease process requires knowledge of its etiology and 
pathogenesis, as well as the availability of methods for prediction of those at high risk for 
this disorder. Hypertensive disorders of pregnancy are disorders of unknown etiology. In 
addition, it is a clinical syndrome rather than a single disease. The possible causes of this 
disease include immunologic factors, genetic factors, dietary factors, preexisting medical 
conditions, or combination of these factors. Therefore it is very unlikely that any single 
intervention will be effective in preventing this syndrome.  
 
The pathophysiological process of PE begins early in pregnancy; effective preventive 
strategies depend on early detection of risk, ideally in the first trimester. First trimester 
screening would clearly represent a major advantage over a second trimester approach 
because it opens prospects for early and more efficient interventions. In addition, first 
trimester screening followed by a second trimester screening may improve the prediction 
of PE by allowing concomitant (data from the same trimester) and/or sequential (data 
from 2 distinct trimesters) combinations between biological and biophysical data. The 
purpose of this study is to develop and validate a practical predictive model for PE, based 
on a combination of tests performed during the routine first and second trimester clinics, 
associating clinical (risk factors), biological (serum maternal biomarker levels) and 
velocimetric (UAD indices) data in high-risk pregnant women. An ideal model will offer 
a good sensitivity at a reasonably low false-positive rate which allows the estimation of a 
woman’s individual risk for PE later in pregnancy and represents a valuable tool in 
clinical practice.  
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2.1.1. Study objectives 
In this study , considering that the hypertensive disorders of pregnancy has multifactorial 
origins which involve fetoplacental and angiogenic factors, the combination of different 
tests represents a promising avenue for the early detection of these disorders. Based on 
the current knowledge, we propose to investigate combinations of uterine artery Doppler 
(uaD) analysis, biochemical tests (in early pregnancy, i.e. circulating maternal plasma 
levels of selected fetoplacental and endothelial biomarkers), socio-demographic and 
obstetrical characteristics as predictive indexes in our screening method. 
2.1.2. Hypothesis: 
The combination of uterine artery Doppler, biochemical tests, socio-demographic and 
obstetrical characteristics will provide a sensitive and specific strategy for an early 
prediction of the hypertensive disorders of pregnancy, leading to optimized management 
and prevention. 
2.1.3. Objectives:  
Primary – To elaborate a multivariable prediction model of hypertensive disorders of 
pregnancy based on the combination of selected maternal serum markers, uterine artery 
Doppler, socio-demographic and obstetrical characteristics during the 1st trimester.   
 
Secondary –  
1. To elaborate a multivariable prediction model of hypertensive disorders of pregnancy 
based on the combination of uterine artery Doppler, socio-demographic and obstetrical 
characteristics during the early 2st trimester (16 to 22 gestational weeks). 
 
2. To elaborate a multivariable prediction model of SGA (small for gestational age) based 
on the combination of selected maternal serum markers, uterine artery Doppler, socio-
demographic and obstetrical characteristics during the 1st trimester. 
 
 3. To determine if the evolution of velocimetric tests between the 1st and 2nd trimesters 
improve the prediction of hypertensive disorders of pregnancy.  
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2.2. Methods 
 2.2.1 Data sources 
This was a prospective cohort screening study for hypertensive disorders of pregnancy in 
unselected low-risk women with singleton pregnancies. It was based on maternal and 
perinatal records of women who booked for maternity care and delivered at Saint-Justine 
hospital, Montreal, in the period between November 2005 and November 2007. Six 
hundreds and seventy healthy women were included in our study. 
 
The study was approved by the Saint-Justine hospital Research Ethics Committee. 
Written informed consent was obtained from the women agreeing to participate in the 
study. 
 
2.2.2. Study design 
2.2.2.1. Population 
Inclusion criteria:  
• Singleton nulliparous pregnancy women 
• More than 18 years old 
• Followed their antenatal care at Saint-Justine hospital in their pregnancy period 
• Expected delivery at Saint-Justine hospital 
 
Exclusion criteria:  
• Multiparous pregnant women 
• Multiple gestations, e.g. twins, triplets, quadruplets 
• Women who had suffered miscarriage or intrauterine death before 24 gestational 
weeks 
• Foetal chromosomal or structural abnormalities 
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2.2.2.2. Definition:  
Gestational hypertension was defined as the onset of hypertension (systolic BP ≥ 140 
mmHg and/or diastolic BP ≥ 90 mmHg) after 20 weeks of gestation which returned to 
normal within 3 months of delivery, without or with proteinuria of no greater than trace 
levels. Hypertension in these women was confirmed after either overnight rest in hospital 
or subsequent repeated BP measurements during the next few days visit. Early onset 
gestational hypertension was defined as gestational hypertension necessitating delivery 
before 37 week’s gestation. 
 
Preeclampsia was defined as two recordings of a systolic / diastolic blood pressure (at 
least one of which is ≥ 140 / 90 mmHg) measured at least 4 hours apart in previously 
normotensive women, and  proteinuria ≥ 300 mg in a 24-hour, or two reading of at least 
2+ on dipstick urinalysis of midstream or catheter urine specimens if  24 hour urine 
collection was unavailable. Eclampsia is diagnosed when convulsions occur in a woman 
with preeclampsia. Early on-set preeclampsia was defined as preeclampsia necessitating 
delivery before 37 week’s gestation. 
 
Small-for-gestational-age (SGA) was defined as a newborn’s birth weight below the 10th 
percentile for gestational age. 
 
Preterm birth was defined as birth before 37 weeks' gestational age. 
 
Gestational age was calculated from the last menstrual period, confirmed by ultrasound 
measurement of crown-rump length at first-trimester. If the date of the last menstrual 
period was not consistent, gestational age was estimated by ultrasound measurement of 
crown-rump length at first-trimester. 
 
2.2.2.3 Measurement: 
Doppler 
For these women, two ultrasound examinations are routinely performed during 
 29
pregnancy. The first, at 11 to 14 weeks, is for pregnancy dating and assessment of risk for 
chromosomal abnormalities by measurement of fetal nuchal translucency thickness. 
The second, at 17 to 21 weeks, is for measurement of fetal growth and examination for 
fetal defects. In the cases where no major fetal defects were detected, women were 
offered the option of participating in the screening study for hypertensive disorder of 
pregnancy.  
 
Uterine artery Doppler studies were performed by transabdominal sonography by 
certificated sonographers.  
 
Women were placed in the semirecumbent position and transabdominal ultrasound was 
used to obtain a view of iliac arteries. Subsequently, color flow mapping was used to 
identify the uterine arteries as aliasing vessels. Pulsed wave Doppler was used to obtain 
flow velocity waveforms from the ascending branch of the uterine artery closest point 
closest. When three similar consecutive waveforms were obtained, the Pulsatility index 
(PI) and Resistance index (RI) were measured, and the mean PI of the left and right 
arteries was calculated. The presence or absence of an early diastolic notch in the 
waveform was recorded. Measurements were performed for both uterine arteries. 
 
Socio-demographic and obstetrical characteristics: 
At the first visit (11 to 14 gestational weeks), patients were asked to complete a 
questionnaire on maternal age, ethnicity, gravidity, parity, height, weight, smoking status, 
medical history (including chronic hypertension, renal disease, diabetes, cardiac disease, 
autoimmune disease, symptomatic hyperthyroidism thrombophilia, etc), obstetric history 
(previous pregnancy outcomes, including the presence of preeclampsia and whether the 
present pregnancy was from a new partner), and family history of preeclampsia (sister, 
mother, or both). 
 
Biochemical markers: 
Maternal blood samples were obtained by venipuncture. All the serum samples for 
measurement of pregnancy associated plasma protein A (PAPP-A), free human chorionic 
gonadotropin-β (β-hCG) , inhibin-A, placental protein 13 (PP13) and a disintegrin and 
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metalloprotease 12 (ADAM12) levels were collected between 11 to 13+6 gestational 
weeks. They were allowed to clot into a nonheparinized tube, and centrifuged.  
Maternal serum free β-hCG , Inhibin-A and PAPP-A were measured over a period of 5 
days on the Kryptor analyzer – a random access immunoassay analyzer using time-
resolved amplified cryptate emission (TETHNICITY) technology – and the CIS 
automated immunofluorescent assays . 
All the samples were shipped to Perkin-Elmer Life and Analytical Sciences (Turku, 
Finland) for analysis of PP13 and ADAM12 using solid-phase sandwich enzyme linked 
immunosorbent assay (ELISA).  
 
All samples were analyzed by an examiner blinded to the clinical outcome. 
 
Medical recorders, Doppler findings, Socio-demographic and obstetrical characteristics, 
and the results of biochemical testing were recorded in a computer database at the time of 
assessment. 
 
Study quality control 
Research nurses were trained for good clinical practice and Standard Operational 
Procedures. All biological tests were performed in the same laboratory under the 
responsibility of one of the co-investigators (ED). The laboratory of our hospital has been 
accredited following monitoring processes involving the assessment of the quality 
laboratory management and technical competence in accordance with the requirements 
of  the  Société du Québec de Biologie Clinique (INTER n QUAL) and of the Ministère de 
la Santé Publique du Québec. 
 
2.2.3 Statistic analysis 
2.2.3.1 Variables 
Dependent variables 
Dependent variables included early on-set preeclampsia, gestational hypertension 
with delivery before 37 gestational weeks, gestational hypertension, preeclampsia, 
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preterm birth and SGA. The factors that were potentially associated with these 
progressions were referred as independent or predictive variables. We assessed the 
sensitivity, specificity, screen-positive value and Likelihood ratios of these models.  
 
Independent variables 
Independent variables were Doppler indexes, maternal serum biochemical markers, 
sociodemographic and obstetrical characteristics. These included: PI, RI, bilateral notch, 
ethnicity, maternal age, smoking, body mass index (BMI), prior history of gestational 
hypertension, history of chronic disease, PAPP-A, β-hCG, inhibin-A, PP13 and 
ADAM12.  
 
All results of maternal serum biochemical marker were expressed as a multiple of the 
median (MoM) in normal pregnancies and adjusted for gestational age. 
SGA and Doppler indexes were expressed as percentiles in normal pregnancies and 
adjusted for gestational age.  
 
 Receiver-operating characteristics (ROC) curve analysis was used to define the 
appropriate cutoff point for the best combination of sensitivity and specificity as follows:  
Mean Pulsatility index ≥ 90 percentiles at the second trimester and IMC =28. (Table 3) 
Because we do not have enough case information (early onset preeclampsia) for the first 
trimester, so we chose“mean Pulsatility index ≥ 95 percentiles at the first trimester”, “the 
presence of protodiastolic bilateral notch”, “free β-hCG ≤0.5MoM”, “ Inhibin-A ≥1.5 
MoM”, “ PAPP-A ≤0.5MoM”, “ADAM12 ≤0.5MoM” and “ PP13≤0.5MoM” as our study 
variable as most related studies suggested. 
 
2.2.3.2 Statistic analysis 
Differences between groups 
The Student t-test was used for normally distributed continuous variables.  
The Mann-Whitney test was used for non-normally distributed variables.  
Chi -square test or Fisher’s exact test was used for categorical variables. 
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Calculation of risk 
Odds ratio (OR) was used as an approximation of the relative risk. An OR approximates 
how much more likely (or unlikely) the outcome is for those with the condition present 
(X=1) than among those with its absent (X=0).  
 
Correlation 
Spearman’s rank correlation was used for a correlation assessment. 
 
Logistic regression analysis 
As a first step, univariable analysis was employed to evaluate individual variables 
(Doppler, biomarkers and maternal characteristics) as potentially significant predictors of 
pre-eclampsia or other outcomes.  
 
Then, multivariable logistic regression analysis was employed to assess the contribution 
of each of these variables to our dichotomous outcomes. We used ‘method: enter’ as the 
model selection method. This algorithm specifies 0.05 as the critical alpha level for 
entering a variable into the model and 0.10 as the significant level for a variable to remain 
in the model.  
Hosmer and Lemeshow Goodness-of-Fit test, chi-square goodness-of-fit test, Cox-Snell 
R2 and Nagelkerke R2 values were used to test whether the model's estimates fit the data 
at an acceptable level or not. 
 
Receiver-operating characteristics (ROC) curve analysis was used to define the best 
predictors for the outcomes examined and to determine the optimal discriminatory point 
with the best combination of sensitivity and specificity. 
 
A descriptive analysis was conducted for characteristics of study population and for 
certain clinical outcomes.  
 
Statistical software 
All calculations were performed with SPSS software (Statistical Package for theSocial 
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Sciences, SPSS Inc, Chicago, USA) version 15.0  
Results were considered to be statistically significant when p < 0.05. 
All tests presented are two-tailed. 
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2.3. Results 
From November 2005 to November 2007, Six hundred and seventy singleton women 
were included in the study. According to our exclusion criteria, thirty five nulliparous 
women with missing data and all the thirty seven multiparous women were excluded. In 
total, the results of five hundred and ninety eight singleton nulliparous women were 
available for analysis.  
 
2.3.1. General descriptions  
Among 598 nulliparous, 20 women developed preeclampsia (3.3%), 7 women developed 
early onset preeclampsia (1.2%), 52 women developed gestational hypertension (8.7%), 
10 women developed gestational hypertension with delivery before 37 weeks (1.7%), 37 
women had a preterm birth (6.2%) and 54 women had a SGA newborn (9.0%). 
 
2.3.1.1. Maternal demographic characteristics 
Table 4 summarizes the maternal demographic characteristics and pregnancy outcomes of 
our study population. Mean maternal age was 29.5 years old and mean birth weight was 
3400 grams. We had 20 pregnant women developed preeclampsia. 
Table 5 shows the comparison results of maternal demographic characteristics between 
cases and no case groups.  
For early onset preeclampsia, gestational hypertension with delivery before 37 weeks, 
and preterm birth (delivery before 37 weeks), the maternal demographic characteristics 
(maternal weight, BMI, ethnic African-Car and chronic disease history) are significantly 
different between cases and the no case groups.  
For preeclampsia, the maternal demographic characteristics (maternal weight, BMI and 
ethnic African-Car) are significantly different between cases and no case groups.  
For gestational hypertension, maternal weight, BMI and chronic disease history are 
significantly different between cases and no case groups.  
For the prediction of SGA (birth weight less than the 10th percentile), these maternal 
demographic characteristics do not differ significantly between cases and no case groups. 
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2.3.1.2. Maternal serum biochemical markers  
Normal pregnancies (no case group) 
Table 6 presents the mean and the median value of maternal serum biochemical markers 
(PAPP-A, free β-hCG, Inhibin-A, PP13 and ADAM12) by gestational age (weeks) in the 
first trimester in normal pregnancies. 
Except for PP13, the mean values and (or) the median values of all the above mentioned 
biochemical markers show significant differences by the gestational age (weeks). 
PAPP-A and ADAM12 are increasing, while free β-hCG and Inhibin-A are decreasing 
between the 11th and the 13+6th gestational weeks. (Figure 7) 
 
Affected pregnancies (case group) 
Table 7 presents the relationship between the serum biochemical markers and the 
outcomes studied.  
Table 7 shows the median MoMs of biomarkers in the outcomes studied. The median 
MoMs were lower at certain degree depending on the biomarkers when compared with 
the median MoM of normal pregnancies, especially for PAPP-A.   
 
In our study, PAPP-A ≤ 0.5MoM was statistically significantly associated with early 
onset preeclampsia, gestational hypertension with delivery before 37 gestational weeks, 
gestational hypertension and preterm birth.  
PP13≤ 0.5MoM was statistically significantly associated with early onset preeclampsia, 
gestational hypertension and SGA. 
 ADAM12 ≤ 0.5MoM was statistically significantly associated with gestational 
hypertension, preterm birth and gestational hypertension with delivery before 37 
gestational weeks.  
Inhibin-A ≥ 1.5 MoM was statistically significantly associated with SGA. 
free β-hCG  ≤0.5MoM was statistically significantly associated with early onset 
preeclampsia and SGA. 
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2.3.1.3. Maternal Doppler results 
Table 9 shows that “mean pulsatility index ≥ the 95th percentiles at the first trimester” has 
statistical significance with SGA, but not with other hypertensive disorders or preterm 
birth. 
“Mean pulsatility index ≥ 90th percentiles at the second trimester” is a very sensitive 
Doppler index. It has statistical significance with all the diseases involved in our study. 
  
As for normal pregnancies, study results show that mean PI has statistical significant 
differences between the gestational weeks with attenuating tendency in the first trimester. 
PI (11weeks) = 1.56, PI (12weeks) = 1.44, PI (13weeks) = 1.27, p<0.001. Mean PI shows 
no statistical difference between 17 and 21+6 gestational weeks (mean PI = 0.92, the 
difference between the gestational weeks p = 0.714) in this study.  (Table 11, Figure 8) 
 
Table 10 describes the presence of bilateral notch in the first and the second trimester and 
their statistical relationship with the diseases being studied. The presences of bilateral 
notch only in the first trimester or the presence of newly-present bilateral notch in the 
second trimester do not show any statistical significance with all the outcomes studied. 
 
On the other hand, ‘Have bilateral notch at second trimester’ and ‘bilateral notch with a 
persistent presence from first trimester to second trimester’ shows statistical significance 
with most outcomes, including early onset preeclampsia, gestational hypertension with 
delivery before 37 gestational weeks, gestational hypertension and SGA.  
 
2.3.2. Prediction of hypertensive disorders of pregnancy in the first 
trimester (11 to 13+6 gestational weeks) 
2.3.2.1. Prediction of early onset preeclampsia 
Univariable and multivariable logistic regression analysis showed that there are seven 
independent variables (PAPP-A≤0.5MoM, PP13 ≤0.5MoM, free β-hCG≤0.5MoM, 
BMI≥28, ethnic African-Car, chronic disease history and maternal age) which were 
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significantly associated with the developing of early onset preeclampsia.  
 
Logistic regression model Formula:    ez / 1+ ez 
 
The formula suggested by this prediction model is: 
 
(Pre36w) z = -10.519 + 0.404 (pappa0.5M) -0.100 (pp13_0.5M) +2.68 (hCG_0.5M) +  
 
2.090 (IMC_28) + 0.851 (Eth_AfC) + 2.795 (Mala_pre) + 0.129 (Age) 
 
Notes: 
pappa0.5M (PAPP-A ≤ 0.5MoM =1, PAPP-A > 0.5MoM =0), 
pp13_0.5M (PP13 ≤ 0.5MoM =1, PP13 > 0.5MoM =0) 
hCG_0.5M (free β-hCG ≤ 0.5MoM =1, free β-hCG > 0.5MoM=0) 
IMC_28 (BMI ≥28 =1, BMI < 28 =0) 
Eth_AfC (ethnic African-Car =1, not ethnic African-Car =0) 
Mala_pre (had chronic disease history =1, had not chronic disease history =0) 
 
Example: 
If a nulliparous singleton pregnant woman who had the following characteristics: 
PAPP-A ≤ 0.5MoM, PP13 ≤ 0.5MoM, free β-hCG ≤ 0.5MoM, BMI ≥28, was African-
Car ethnic race, had chronic disease history and at 30 years old,  
then: 
 
(Pre36w) z = -10.519 + 0.404 (1) -0.100 (1) +2.68 (1) + 2.090 (1) + 0.851 (1) + 2.795 (1) 
+ 0.129 (30) 
 
z = 2.071 
 
P (probability for developing early onset preeclampsia) = exp (2.071) / [1 + exp (2.071)],  
P = 88.8% 
Therefore, this pregnant woman would be estimated to have 88.8% probability of 
developing preeclampsia. 
Using the P = 0.50 as the cut-off point, its corresponding area under ROC curve was 
94.9% (95%CI: 90.4% -- 99.5%) 
In our study, we wanted a false positive value less than 10%. For this predictive model, 
according to ROC curve, we choose a false positive value = 3%, then the validity 
parameters of the model were as follow: 
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Sensitivity = 71.4%, specificity = 97% and a positive likelihood ratio = 23.8 
 
2.3.2.2. Prediction of gestational hypertension with delivery before 37 weeks 
Univariable and multivariable logistic regression analysis showed that there are six 
independent variables (PAPP-A≤0.5MoM, ADAM12 ≤0.5MoM, BMI≥28, ethnic 
African-Car, chronic disease history and maternal age) which were significantly 
associated with the developing of gestational hypertension with delivery before 37 weeks. 
 
The formula suggested by this prediction model is: 
 
(Htag36w) z = -7.842 + 1.187 (pappa0.5M) + 0.963 (adam12_0.5M) + 1.198 
(IMC_28)  
 
+ 1.644 (Eth_AfC) + 1.698 (Mala_pre) + 0.086 (Age) 
 
Notes: 
pappa0.5M (PAPP-A ≤ 0.5MoM =1, PAPP-A > 0.5MoM =0), 
adam12_0.5M (adam12 ≤ 0.5MoM =1, adam12 > 0.5MoM =0) 
IMC_28 (BMI ≥28 =1, BMI < 28 =0) 
Eth_AfC (ethnic African-Car =1, not ethnic African-Car =0) 
Mala_pre (had chronic disease history =1, had not chronic disease history =0) 
 
Example: 
If a nulliparous singleton pregnant woman who had the following characteristics: 
PAPP-A ≤ 0.5MoM, ADAM12 ≤ 0.5MoM, BMI ≥28, was African-Car ethnic race, had 
chronic disease history and at 30 years old,  
then: 
 
(Htag36w) z = -7.842 + 1.187 (1) + 0.963 (1) + 1.198 (1) + 1.644 (1) + 1.698 (1)  
 
+ 0.086 (30) 
 
z = 1.43 
 
P (probability for developing gestational hypertension with delivery before 37 weeks) 
= exp (1,43) / [1 + exp (1,43)], 
 P = 80.7% 
Therefore, this pregnant woman would be estimated to have 80.7% probability of 
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developing gestational hypertension with delivery before 37 weeks. 
 
Using the P = 0.50 as the cut-off point, its corresponding area under ROC curve was 
85.2% (95%CI: 71.9% -- 98.6%) 
According to ROC curve, we choose a false positive value = 8.5%, then the validity 
parameters of the model were:  
Sensitivity = 60.0%, specificity = 91.5% and a positive likelihood ratio = 7.1 
 
2.3.2.3. Prediction of other hypertensive disorders of pregnancies, preterm birth and 
SGA 
Table 12 part 1 shows that from 11 to 13+6 gestational weeks our predictive models of 
preeclampsia, gestational hypertension, preterm birth and SGA do not have an optimum 
area under the ROC curve (Less than 75%) or a good sensitivity when we choose a false 
positive value around 10%. 
Therefore, our models do not provide good predictive value for the diseases mentioned 
above in the first trimester. 
 
 
2.3.3. Prediction of hypertensive disorders of pregnancy in second 
trimester (17 to 21+6 gestational weeks) 
 
2.3.3.1. Prediction of early onset preeclampsia 
Univariable analysis showed that the independent variables (PAPP-A≤0.5MoM, PP13 
≤0.5MoM, free β-hCG≤0.5MoM, BMI≥28, ethnic African-Car, chronic disease 
history, maternal age, mean pulsatility index ≥ the 90 percentile and bilateral notch with 
a persistent presence from first trimester to second trimester) were significantly 
associated with developing early onset preeclampsia.  
In multivariable logistic regression analysis, PAPP-A≤0.5MoM, PP13 ≤0.5MoM and 
maternal age were removed in our model because their p value are higher than 0.100. In 
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our model, following parameters were significantly associated with developing of early 
onset preeclampsia: free β-hCG≤0.5MoM, BMI≥28, ethnic African-Car, chronic 
disease history, mean pulsatility index ≥ 90 percentiles and bilateral notch with a 
persistent presence from the first trimester to second trimester. 
 
The formula suggested by this prediction model is: 
 
(Pre36w) z = (Pre36w) z = -8.768 + 3.614 (hCG_0.5M) + 1.212 (IMC_28) + 0.326  
 
(Eth_AfC) + 2.164 (Mala_Pre) + 3.539 (PI2_per90) + 1.693 (notchB_con) 
 
Notes: 
hCG_0.5M (free β-hCG ≤ 0.5MoM =1, free β-hCG > 0.5MoM=0) 
IMC_28 (BMI ≥28 =1, BMI < 28 =0) 
Eth_AfC (ethnic African-Car =1, not ethnic African-Car =0) 
Mala_pre (had chronic disease history =1, had not chronic disease history =0) 
PI2_per90 (mean pulsatility index ≥ 90 percentiles = 1, mean pulsatility index < 90 percentiles = 0) 
notchB_con (bilateral notch with a persistent presence from first trimester to second trimester =1, otherwise 
=0) 
 
Example: 
If a nulliparous singleton pregnant woman who had the following characteristics: 
free β-hCG ≤ 0.5MoM, BMI ≥28, was African-Car ethnic race, had chronic disease 
history, mean pulsatility index ≥ 90 percentiles and bilateral notch with a persistent 
presence from first trimester to second trimester,  
then: 
 
(Pre36w) z = -8.768 + 3.614 (1) + 1.212 (1) + 0.326 (1) + 2.164 (1) + 3.539 (1) + 1.693 
(1) 
 
z = 3.78 
 
P (probability for developing early onset preeclampsia) = exp (3.78) / [1 + exp (3.78)],  
 P = 97.8% 
Therefore, this pregnant woman would be estimated to have 97.8% probability of 
developing preeclampsia. 
Using the P = 0.50 as the cut-off point, its corresponding area under ROC curve was 
97.5% (95%CI: 94.7% -- 100.0%) 
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For this predictive model, according to ROC curve, we choose a false positive value = 
9.9%, then the validity parameters of the model were as follow: 
Sensitivity = 100%, specificity = 90.1% and a positive likelihood ratio = 10.1 
 
2.3.3.2. Prediction of gestational hypertension with delivery before 37 weeks 
Univariable analysis showed that there are eight independent variables (PAPP-
A≤0.5MoM, ADAM12 ≤0.5MoM, BMI≥28, ethnic African-Car, chronic disease 
history maternal age, mean pulsatility index ≥ 90 percentiles and bilateral notch with a 
persistent presence from first trimester to second trimester) which were significantly 
associated with developing gestational hypertension with delivery before 37 weeks. 
In multivariable logistic regression analysis, maternal age was removed in our model 
because p value is higher than 0.100. In this model, parameters which were significantly 
associated with developing gestational hypertension with delivery before 37 weeks 
includes PAPP-A≤0.5MoM, ADAM12 ≤0.5MoM, BMI≥28, ethnic African-Car, 
chronic disease history, mean pulsatility index ≥ 90 percentiles and bilateral notch with 
a persistent presence from the  first trimester to second trimester. 
 
The formula suggested by this prediction model is: 
 
(Htag36w) z = -5.970 + 0.273 (pappa0.5M) + 1.918 (adam12_0.5M) + 1.015 
(IMC_28)  
 
+ 1.206 (Eth_AfC) + 1.317 (Mala_Pre) + 2.692 (PI2_per90) + 0.742 (notchB_con) 
 
Notes: 
pappa0.5M (PAPP-A ≤ 0.5MoM =1, PAPP-A > 0.5MoM =0), 
adam12_0.5M (adam12 ≤ 0.5MoM =1, adam12 > 0.5MoM =0) 
IMC_28 (BMI ≥28 =1, BMI < 28 =0) 
Eth_AfC (ethnic African-Car =1, not ethnic African-Car =0) 
Mala_pre (had chronic disease history =1, had not chronic disease history =0) 
PI2_per90 (mean pulsatility index ≥ 90 percentiles = 1, mean pulsatility index < 90 percentiles = 0) 
notchB_con (bilateral notch with a persistent presence from first trimester to second trimester =1, otherwise 
=0) 
 
Example: 
If a nulliparous singleton pregnant woman who had the following characteristics: 
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PAPP-A ≤ 0.5MoM, ADAM12 ≤ 0.5MoM, BMI ≥28, was African-Car ethnic race, had 
chronic disease history, mean pulsatility index ≥ the 90 percentile and bilateral notch with 
a persistent presence from first trimester to second trimester,  
then: 
 
(Htag36w) z = -5.970 + 0.273 (1) + 1.918 (1) + 1.015 (1) + 1.206 (1) + 1.317 (1)  
 
+ 2.692(1) + 0.742 (1) 
 
z = 3.193 
 
P (probability for developing gestational hypertension with delivery before 37 weeks) 
= exp (3.193) / [1 + exp (3.193)], 
 P = 96.1% 
Therefore, this pregnant woman would be estimated to have 96.1% probability of 
developing gestational hypertension with delivery before 37 weeks. 
 
Using the P = 0.50 as the cut-off point, its corresponding area under ROC curve was 
87.4% (95%CI: 71.7% -- 100.0%) 
According to ROC curve, we choose a false positive value = 4.3%, then the validity 
parameters of the model were:  
Sensitivity = 77.8%, specificity = 85.7% and a positive likelihood ratio = 8.1 
 
2.3.3.3. Prediction of preeclampsia 
Univariable and multivariable logistic regression analysis showed that there are five 
independent variables (PAPP-A≤0.5MoM, ethnic African-Car, BMI≥28, maternal age 
and mean pulsatility index ≥ the 90 percentile) which were significantly associated with 
developing preeclampsia. 
 
The formula suggested by this prediction model is: 
 
(Pre) z = -7.524 + 0.840 (pappa0.5M) + 0.830 (Eth_Afc) + 1.246 (IMC_28) + 0.098  
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(Age) + 1.461 (PI2_per90) 
 
Notes: 
pappa0.5M (PAPP-A ≤ 0.5MoM =1, PAPP-A > 0.5MoM =0), 
IMC_28 (BMI ≥28 =1, BMI < 28 =0) 
Eth_AfC (ethnic African-Car =1, not ethnic African-Car =0) 
Mala_pre (had chronic disease history =1, had not chronic disease history =0) 
PI2_per90 (mean pulsatility index ≥the 90 percentile = 1, mean pulsatility index < the 90 percentile = 0) 
 
Example: 
If a nulliparous singleton pregnant woman who had the following characteristics: 
PAPP-A ≤ 0.5MoM, was African-Car ethnic race, had chronic disease history, BMI ≥28 
and mean pulsatility index ≥the 90 percentile, 
then: 
 
(Pre) z = -7.524 + 0.840 (1) + 0.830 (1) + 1.246 (1) + 0.098 (1) + 1.461 (1) 
 
z = 3.049 
 
P (probability for developing preeclampsia) 
= exp (3.049) / [1 + exp (3.049)], 
 P = 95.5% 
Therefore, this pregnant woman would be estimated to have 95.5% probability of 
developing preeclampsia. 
 
Using the P = 0.50 as the cut-off point, its corresponding area under ROC curve was 
75.0% (95%CI: 60.0% -- 90.0%) 
According to ROC curve, we choose a false positive value = 9.1%, then the validity 
parameters of the model were:  
Sensitivity = 60.0%, specificity = 90.9% and a positive likelihood ratio = 6.6 
 
2.3.3.4. Prediction of other hypertensive disorders of pregnancies, preterm birth and  
SGA 
Table 12 part 2 shows that between 17 and 21+6 gestational weeks our predictive models 
of gestational hypertension, preterm birth and SGA do not have a good area under the 
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ROC curve (Less than 75%) or a good sensitivity at the false positive value of around 
10%. 
Therefore, our models do not have good predictive value for the above mentioned 
diseases in the second trimester. 
 
As a summary for our study results, mean PI at the 2nd trimester as a single marker had 
the highest sensitivity (83.3%) and specificity (88.5%) in the screening test of 
preeclampsia with a false positive value of 11.5%, LR = 7.2 (p=0.003). Compared with 
mean PI, the predictive value of “the presence of persistent bilateral notch” was lower 
(sensitivity 66.7%, specificity 83.9%, FPV 16.1%, LR 4.1, p=0.033). Analysis of 
different combinations revealed that the combination of maternal characteristics has 
higher predictive values (sensitivity 83.3%, specificity 91.0%, FPV 9.0%, LR 9.3, 
p=0.002) than the combination of maternal serum biomarkers (sensitivity 66.7%, 
specificity 88.5%, FPV 11.5%, LR 5.8, p=0.032). The combination of maternal 
characteristics, maternal serum and uterine artery Doppler has the best predictive values 
(sensitivity 100%, specificity 90.1%, FPV 9.9%, LR 10.1, p<0.001). (Table 12, Table 13, 
Figure 9) 
 
After our multivariable logistic regression analysis, we got the good predictive models for 
early onset preeclampsia and gestational hypertension with delivery before 37 weeks in 
the second trimester.  We got the moderate predictive models for preeclampsia in the 
second trimester, early onset preeclampsia and gestational hypertension with delivery 
before 37 weeks in the first trimester. (Table 12) 
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Conclusion 
The purpose of this thesis is to improve our screening method for the prediction and risk 
estimation of hypertensive disorders of pregnancy, preterm birth and SGA in the first and 
second trimester in the antenatal health care unit.  
  
The research was based on maternal characteristic information, biochemical analysis, 
Doppler results and statistical data from medical files, with the purpose of looking for an 
improved screening method which is simple, inexpensive, reproducible, widely and easily 
used, non-invasive and can be carried out in early pregnancy to allow for more efficient 
preventive or therapeutic intervention. 
 
Maternal demographic characteristics  
 
Comparing the results of maternal demographic characteristics between the case group 
and the no case group, our findings show that:  
Increased maternal BMI (≥28) was the most popular and important factor leading to 
hypertensive disorders of pregnancy and preterm birth. This result agrees with the theory 
that obese and preeclamptic women share common features such as dyslipidemia, 
hyperinsulinemia, insulin resistance and impaired endothelial function, which are related 
to inflammation and altered vascular function. These shared features are consistent with 
the premise that obesity is a risk factor for preeclampsia due to preexisting inflammation 
and inflamed vasculature.102 
“Ethnic African-Car” and “had a chronic disease history” were the second and the third 
major risk factors for developing these diseases. African Americans are known as one of 
the ethnic group that has the highest rate of hypertension and diabetes mellitus in the 
world35,103. The underlying genetic factors may have a strong relationship with 
developing hypertensive disorders of pregnancy, same as those observed in chronic 
disease conditions. 
The last risk factor is the older maternal age. In our study, we excluded women less than 
18 years old of age. So we could not find the contribution of teenage pregnancies.  
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But for SGA, these maternal demographic characteristics did not differ significantly 
between SGA and non-SGA groups. 
 
Maternal serum biomarkers 
 
The biochemical tests, which compared normal pregnant women with those who 
developed hypertensive disorders of pregnancy, show that: 
“Maternal serum PAPP-A level ≤ 0.5 MoM” was the most sensitive biomarker for 
hypertensive disorders of pregnancy and preterm birth.  
“ADAM12≤ 0.5 MoM, PP13≤ 0.5MoM” were good predictive biomarkers for the 
gestational hypertension.  
“Inhibin-A ≥1.5 MoM” was found to have statistic significance with SGA, but not with 
hypertensive disorders of pregnancy and preterm birth. Note that our serum samples were 
collected in the first trimester (11 to 13+6 weeks). S.Mut. mentioned that inhibin A has 
better predictive value of hypertensive disorders at later gestational weeks.104 Therefore, 
we need further studies to verify that. 
 
Doppler results 
 
Lots of researchers suggest that pregnancies with increased risk of developing 
hypertensive disorders and related complications already have abnormally increased 
uterine artery pulsatility index in early pregnancy. This provides a very useful predictive 
value for early onset preeclampsia. In our study, however, “mean pulsatility index ≥ the 
95 percentile at first trimester” only showed statistical significance with SGA, not with 
other hypertensive disorders or preterm birth. This could be due to the small sample size 
of our study -- only 7 cases of early onset preeclampsia with 2 of them not having 
complete Doppler information in the first visit. This affects the reliability of our study 
result. 
As for normal pregnancies, our study results show that mean PI has statistical significant 
differences by gestational age with attenuating tendency in the first trimester.  
This decrease in vascular resistance in fetoplacental circulation with advancing gestation 
could be the consequence of the increase in the number of vessels, and their relative 
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volume, within the chorionic villi and an expansion of the intervillous circulation as 
evidenced by the coinciding fall in uterine arterial resistance. This agrees with the 
findings in some previous studies which suggested that the fall in fetoplacental vascular 
resistance with increasing gestation could lead to a reduction in the fetal cardiac workload 
in normal pregnancies.105 
 
“Mean pulsatility index ≥ the 90th percentile in the second trimester” is a very sensitive 
Doppler index. It showed statistical significance with all the outcomes in our study. This 
result indicates that in this gestational stage the abnormal uterine artery circulation 
developed more and more visibly. This is due to the fact that the process of physiological 
adaptation of the spiral arteries is usually completed around 22nd weeks of pregnancy. 
Therefore, Doppler assessment of the uterine arteries at second trimester is a useful tool 
in determining whether placentation has developed normally. Hence mean PI became one 
of the most reliable parameters in our screening program. 
In normal pregnancies, mean PI showed no statistical difference between 17 and 21+6 
gestational weeks in this study. This is different than that in the first trimester.  
 
Studies showed that the persistence of an early diastolic “notch” in the flow velocity 
waveform indicates an insufficient physiological conversion of the spiral arteries and it 
depended mainly on vessel wall compliance. This is different than PI which is determined 
by vascular resistance distal to the uterine artery. 106  
Hence, “presence of bilateral notch” became another independent Doppler index which 
has also been extensively studied.  
Our study analyzed the relationship between the diseases interested and the five notch 
conditions – “have bilateral notch at first trimester”, “have bilateral notch at second 
trimester”, “the presence of bilateral notch only at first trimester”, “newly-present 
bilateral notch at second trimester”, and “bilateral notch with a persistent presence from 
first trimester to second trimester”. 
Our results showed that “have bilateral notch at second trimester” and “bilateral notch 
with a persistent presence from first trimester to second trimester” has statistical 
significance with most of the outcomes studied, including early onset preeclampsia, 
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gestational hypertension, gestational hypertension with delivery before 37 weeks and 
SGA. Meanwhile, “have bilateral notch at first trimester” , “the presence of bilateral 
notch only at first trimester” or “newly-present bilateral notch at second trimester” failed 
to show any statistical significance with any of the diseases interested in our study. 
Hence, we chose “bilateral notch with a persistent presence from the first trimester to the 
second trimester” as a predictor in our logistic regression model. 
 
Based on the previous study results, we decided to develop a combinative screening 
method which combines the advantages of each single screening method. 
ROC analysis revealed that the combination of maternal characteristics, maternal serums 
and uterine artery Doppler in the second trimester have significant predictive values for 
hypertensive disorders, preterm birth and SGA in second trimester. 
In our study, mean PI at the 2nd trimester as a single marker had the highest sensitivity 
and specificity in the screening test of preeclampsia. Compared to mean PI, the predictive 
value of “the presence of persistent bilateral notch” was lower. Analysis of different 
combinations revealed that the combination of maternal characteristics has higher 
predictive values than the combination of maternal serum biomarkers. The combination 
of maternal characteristics, maternal serums and uterine artery Doppler has the best 
predictive values  
 
In addition, screening with a combination of maternal characteristics, serum biomarkers 
and uterine artery Doppler was found to be particularly effective in identifying women 
who develop severe early onset preeclampsia rather than late onset disease, preterm birth 
or SGA. For a false-positive rate of 10%, the sensitivity for early onset preeclampsia was 
71.4% compared to 57.9% for late preeclampsia in the first trimester, and 100% 
compared to 60% for late preeclampsia in the second trimester. This is particularly 
important because it is the early preeclampsia rather than the late preeclampsia that is 
associated with increased risks of perinatal mortality and morbidity as well as both short-
term and long-term maternal complications. 
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No statistically significant relationship was found between the hypertensive disorders and 
Doppler indexes (mean PI, presence of bilateral notch) in the first trimester. After 
combining the maternal characteristics with serum biomarkers, some predictive values 
were obtained, but no as good as those in the second trimester.  
 
Suggestions for future work 
This study has the limitation of being a single-center study with small sample size and not 
having enough Doppler information in the first trimester. This limitation could be 
overcome in future studies with longer time period and increased number of participants.  
 
Meanwhile, our studies have demonstrated the potential value of first-trimester screening 
for hypertensive disorders of pregnancy with a combination of maternal characteristics, 
maternal serum testing and sonographic assessment. Our models allow the identification 
of women requiring increased surveillance throughout pregnancy or preventive 
treatments such as low-dose aspirin or heparin. Moreover, it is a pragmatic approach: the 
predictive model was successful in identifying women at higher risk of early onset PE, 
the most clinically relevant form of the disease; it is quite easy to implement this new 
screening as an add-on procedure to the current Down’s syndrome screening, taking 
advantage of an existing screening program at a relatively low cost. This integration in 
existing prenatal screening enables an easier transfer of new knowledge into clinical 
practice.  
 
In conclusion, our study shows that the mean PI at 2nd trimester has the highest predictive 
efficacy among the markers being analyzed. The results indicate that maternal 
characteristics are suffic effic important in screening for the preeclampsia. Serum 
biomarkers have modest efficacy in our predictive models. However, adding these 
maternal measurements to uterine artery Doppler velocimetry results in a clinically 
significant improvement in the prediction of hypertensive disorders of pregnancy.  
 
The efficacy of this screening method is to be further verified in our ongoing study with 
increased sample sizes. Whether early therapeutic intervention in high-risk groups can 
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reduce the prevalence of the disease also remains to be determined. If a successful model 
is obtained, randomized controlled trials will become feasible in high-risk populations.  
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LIST OF TABLES 
 
Table 1. Effect of hypertensive disorders in pregnancy on small for gestational age (< the 10th 
percentile) and stillbirth  
 
CI denotes Confidence interval. * Adjusted for smoking, maternal age, gestational diabetes, pre-
existing diabetes, maternal anemia, nulliparity, marital status, drug abuse, prepregnancy weight, 
weight gain, antenatal steroids, twins and infant sex. ** Adjusted for smoking, maternal 
autoantibodies, maternal age, pre-existing diabetes, maternal anemia,prepregnancy weight and 
twins. 
(From: Allen, V.M et al. The effect of hypertensive disorders in pregnancy on small for gestational age and 
stillbirth: a population based study. BMC Pregnancy Childbirth 4,2004) 
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Table 2. Risk factors of hypertensive disorders of pregnancy  
Pregnancy associated risk factors 
• Nulliparity / Multiple / polyhydramnios /Primipaternity /Teenage pregnancy 
• Older age /Interval between pregnancies 
• Previous history of preeclampsia 
• Limited sperm exposure, Donor insemination, Oocyte donation 
• Partner  who fathered a preeclamptic  pregnancy 
• Hydrops fetalis 
• Hydatidiform moles 
Chronic risk factors 
• Chronic hypertension, renal disease, cardiovascular disease 
• Obesity, insulin resistance  
• Gestational , type 1 and type 2 diabetes 
• Activated protein kinase C resistance 
• Protein S deficiency 
• Antiphospholipid antibodies 
• Hyperhomocysteinemia 
• Sick cell disease, sickle cell trait 
• Urinary infection 
Hereditary risk factors 
• Family history of preeclampsia 
• Ethnicity (African-American and Hispanic women in the US) 
• Structural congenital anomalies 
• Chromosomal anomalies (trisomy 13, triploidy) 
Other risk factors 
• Stress, work related psychosocial strain 
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Table 3. Receiver-operating characteristics (ROC) curve analysis for appropriate cutoff point of 
IMC and Mean Pulsatility index at the second trimester. 
 
 
Index Chose value Sensibility 1 - Specificity percentiles  Area under curve 
(95%CI ) (%) 
p 
IMC 28 0.778 0.130  79.3 (61.2-97.3) 0.008 Preterm+PE  
PI2 1.265 1.00 0.099 90 94.6 (91.1-98.1) 0.000 
Preterm+PE : Delivery before 37 gestational weeks + Preeclampsia 
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Table 4. Demographic characteristics and pregnancy outcomes of the study population (n = 598) 
Maternal variables N Mean Median Minimum Maximum Range 
Maternal age (years) 598 29.5 29.0 18.0 43.0 25.0 
Weight (kg) 598 64.3 61.5 41.8 148.4 106.6 
BMI 594 23.8 22.5 17.0 50.0 33.0 
Height (m) 594 1.6 1.65 1.2 1.9 .6 
Birth weight (g) 598 3339.5 3400.0 645.0 4850.0 4205.0 
Gestational age (weeks) 595 39.1 39.0 24.0 42.0 18.0 
 N  Frequency Percent 
Caucasian 486 81.3 
African-American 37 6.2 
Mid-Eastern 27 4.5 
Hispanic 17 2.8 
Asian 9 1.5 
Ethnic group  598 
Mixed/others 22 3.7 
No chronic disease  566 94.6 
diabetics 4 .7 
Chronic hypertension  7 1.2 
Renal disease  3 .5 
Cardiac disease 7 1.2 
Autoimmune disease  4 .7 
Symptomatic hyperthyroid 1 .2 
Have chronic diseases 
before this pregnancy 
598 
Thrombophilia 6 1.0 
New father  582 97.3 
Not a new father  15 2.5 
Partner information  597 
 Has a preeclampsia 
history wife 
1 6.7 
Nonsmoker 563 94.1 Smoking status 
 
598 
Smoker 35 5.9 
Male 301 50.3 Baby sex  598 
Female 297 49.7 
vaginal 451 75.9 Delivery mode 
 
594 
Caesarean 143 24.1 
Eclampsia 0 00.0 
Preeclampsia 20 3.3 
Gestational hypertension 52 8.7 
Early-onset preeclampsia 7 1.2 
Hypertensive disorders of 
pregnancies 
598 
Gestational hypertension with 
delivery before 37 weeks 
10 1.7 
Preterm birth 598 37 6.2 
SGA (≤10 percentiles) 598 54 9.0 
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Table 5. Prescriptive demographic characteristics stratified by selected outcomes  
Age 
N Mean (95%CI) years  
yes no yes no 
p 
Preterm+PE 7 585 32.4(28.6—36.3) 29.5(29.2—29.9) .107 
Preterm+GH 10 582 32.0 (29.1—35.0) 29.5 (29.2—29.9) .088 
Preterm 36 556 29.8 (28.2—31.3) 29.5 (29.2—29.9) .413 
PE 20 572 31.5 (29.6—33.4) 29.5 (29.1—29.9) .066 
GH 52 540 29.9 (28.6—31.2) 29.5 (29.1—29.9) .689 
SGA 54 538 29.2 (28.0—30.5) 29.6 (29.2—29.9) .716 
BMI 
N Mean (95%CI)  
yes no yes no 
p 
Preterm+PE 7 581 30.5 (23.7—37.3) 23.7 (23.4—24.1) .008 
Preterm+GH 10 578 30.2 (25.0—35.4) 23.7 (23.4—24.1) .001 
Preterm 36 552 26.5 (24.3—28.7) 23.7 (23.3—24.0) .010 
PE 20 568 27.6 (25.1—30.2) 23.7 (23.3—24.1) .001 
GH 52 536 27.5 (25.8—29.2) 23.5 (23.1—23.8) .001 
SGA 54 534 24.4 (22.9—25.9) 23.8 (23.4—24.2) .921 
Weight 
N Mean (95%CI) kg  
yes no yes no 
p 
Preterm+PE 7 585 81.8 (62.8—101.0) 64.1 (63.0—65.1) .021 
Preterm+GH 10 582 80.8(66.3—95.3) 64.1 (63.0—65.0) .009 
Preterm 36 556 71.2(65.3—77.1) 63.8 (62.8—64.9) .021 
PE 20 572 74.5(67.3—81.8) 63.9 (62.9—64.9) .001 
GH 52 540 73.8(69.0—78.5) 63.4 (62.3—64.4) .001 
SGA 54 538 64.4(60.3—68.5) 64.3 (63.2—65.3) .361 
Gestational weeks 
N Mean (95%CI) weeks  
yes no yes no 
p 
Preterm+PE 7 585 35.0(34.1—36.0) 39.1 (39.0—39.3) .001 
Preterm+GH 10 582 35.2(34.5—35.9) 39.1 (39.0—39.3) .001 
Preterm 36 556 34.4(33.5—35.3) 39.4 (39.3—39.5) .001 
PE 20 572 37.6(36.5—38.6) 39.1 (39.0—39.3) .001 
GH 52 540 38.2(37.7—38.7) 39.1 (39.0—39.3) .001 
SGA 54 538 39.1(38.9—39.2) 39.1 (38.4—39.3) .323 
Birth weight 
N Mean (95%CI) grams  
yes no yes no 
p 
Preterm+PE 7 585 1914.6(1491.6—2337.5) 3357.2(3317.9—3396.4) .001 
Preterm+GH 10 582 2126.2(1763.6—2488.8) 3361.0(3321.8—3400.1) .001 
Preterm 36 556 2311.9(2109.0—2515.0) 3406.7(3371.5—3441.8) .001 
PE 20 572 2819.5(2411.4—3227.6) 3358.3(3318.9—3397.8) .002 
GH 52 540 3057.5(2866.2—3248.8) 3367.3(3326.9—3407.7) .001 
SGA 54 538 2652.5(2547.9—2757.1) 3409.1(3369.8—3448.5) .001 
Ethnic African-Car 
N Percentage (%) Chi-Square  
yes no yes no Pearson Fisher’s 
Odds Ratio 
(95% CI) 
Preterm+PE 2 /7 35/588 28.6 6.0  .065 6.3(1.2—33.7) 
Preterm+GH 3 /10 34/585 30.0 5.8  .020 6.9(1.8—28.1) 
Preterm 8 /37 29/558 21.6 5.2 .001  5.0(2.1—12.0) 
PE 5 /20 32/578 25.0 5.5  .005 5.7(1.9—16.6) 
GH 6 /52 31/546 11.5 5.7 .094  2.2(0.9—5.5) 
SGA 6 /54 31/538 11.1 5.8 .122  2.0(0.8—5.1) 
Chronic disease history* 
N Percentage (%) Chi-Square  
yes no yes no Pearson Fisher’s 
Odds Ratio 
(95% CI) 
Preterm+PE 3 /7 29/588 42.9 4.9  .004 14.5(3.1—67.6) 
Preterm+GH 4 /10 28/585 40.0 4.8  .001 13.3(3.5—49.7) 
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Preterm 6 /37 26/558 16.2 4.7 .003  4.0(1.5—10.3) 
PE 3 /20 29/578 15.0 5.0  .085 3.3(0.9—12.1) 
GH 6 /52 26/546 11.5 4.8 .050  2.6(1.02—6.7) 
SGA 5 /54 27/538 9.3 5.0  .200 1.9(0.7—5.2) 
BMI= weight / height2  
Preterm+PE : Delivery before 37 gestational weeks + Preeclampsia  
Preterm+GH : Delivery before 37 gestational weeks + Gestational hypertension  
Preterm : Preterm birth, delivery before 37 gestational weeks 
PE : Preeclampsia 
GH : Gestational hypertension 
SGA: birth weight less than the 10th percentile 
*Chronic disease history (at least has one of them): diabetes, chronic hypertension, thrombophilie, 
symptomatic hyperthyroid, autoimmune, renal and cardiac disease. 
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Table 6. Maternal serum biochemical markers in *normal pregnancies from 11 to 13+6 gestational 
weeks 
PAPP-A (IU/L) 
n p  
n mean (95%CI) 
 
 
Std.deviation 
 
median > median ≤ median  
11w 107 1.70 (1.51—1.88) .96 1.45 25 82 .001 
12w 315 2.89 (2.68—3.11) 1.95 2.39 149 166  
13w 165 4.44 (3.95—4.93) 3.49 3.77 115 50  
Free β-hCG (µg/L)   
11w 100 59.79 (52.82—66.75) 35.10 54.45 58 42 .034 
12w 286 59.52 (54.68—64.36) 41.60 48.15 143 143  
13w 151 50.18 (45.29—55.07) 30.40 40.80 67 84  
Inhibin-A (ng/L)   
11w 86 315.17 (285.20—345.15) 139.82 281.20 49 37 .004 
12w 241 288.75 (271.38—306.13) 136.94 254.20 122 119  
13w 123 251.62 (231.14—272.11) 114.75 238.30 55 68  
PP13 (pg/ml)   
11w 78 81.99 (74.86—89.11) 31.61 77.39 41 37 .867 
12w 211 79.92 (75.95—83.89) 29.25 75.77 105 106  
13w 109 81.66 (72.76—90.57) 46.91 73.65 53 56  
ADAM12 (ng/ml)   
11w 78 494.68 (453.66—529.70) 168.65 474.00 24 54 .001 
12w 211 575.69 (549.58—601.80) 192.41 534.00 99 112  
13w 109 663.12 (623.30—702.94) 209.76 658.00 76 33  
*Normal pregnancies: pregnancies without adverse outcomes  
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Table 7. The relationship between serum biochemical markers and diseases studied 
PAPP-A ( ≤ 0.5MoM) 
N Percentage (%)  
total yes no yes no 
Odds Ratio  
(95% CI) 
 
P 
Preterm+PE 585 4 / 7 125 / 578 57.14 21.63 4.83 (  1.07—21.87) 0.05 
Preterm+GH 585 6 / 10  123 / 575 60.00 21.39 5.51 (  1.53—19.84) 0.01 
Preterm 585 13 / 37  116 / 548 35.14 21.17 2.02 (  1.00—4.08) 0.05 
PE 587 9 / 19  121 / 568 47.37 21.30 3.33 (  1.32—8.37) 0.01 
GH 587 24 / 51  106 / 536 47.06 19.78 3.61 (  2.00—6.50) 0.001 
SGA 582 15 / 53  113 / 529 28.30 21.36 1.45 (  0.77—2.74) 0.25 
Free β-hCG  ( ≤ 0.5MoM) 
Preterm+PE 585 3 / 7  60 / 578 42.86 10.38 6.48 (  1.42—29.62) 0.03 
Preterm+GH 585 3 / 10  60 / 575 30.00 10.43 3.68 (  0.93—14.60) 0.08 
Preterm 585 4 / 37  59 / 548 10.81 10.77 1.00 (  0.34—2.94) 1.00 
PE 587 3 / 19  61 / 568 15.79 10.74 1.56 (  0.44—5.50) 0.45 
GH 587 7 / 51  57 / 536 13.73 10.63 1.34 (  0.58—3.11) 0.50 
SGA 582 11 / 53  52 / 529 20.75 9.83 2.40 (  1.17—4.95) 0.02 
Inhibin-A  ( ≥ 1.5MoM) 
Preterm+PE 493 1 / 7  96 / 486 14.29 19.75 0.68 (  0.08—5.69) 1.00 
Preterm+GH 493 1 / 10 96 / 483 10.00 19.88 0.45 (  0.06—3.58) 0.70 
Preterm 493 7 / 33  90 / 460 21.21 19.57 1.11 (  0.47—2.63) 0.82 
PE 494 4 / 15  93 / 479 26.67 19.42 1.51 (  0.47—4.85) 0.51 
GH 494 6 / 44  91 / 450 13.64 20.22 0.62 (  0.25—1.52) 0.30 
SGA 492 4 / 49  93 / 443 8.16 20.99 0.34 (  0.12—0.95) 0.04 
ADAM12  ( ≤ 0.5MoM) 
Preterm+PE 438 1 / 7  11 / 431 14.29 2.55 6.36 (  0.71—57.43) 0.18 
Preterm+GH 438 2 / 10  10 / 428 20.00 2.34 10.45 (  1.96—55.60) 0.03 
Preterm 438 3 / 32  9 / 406 9.38 2.22 4.56 (  1.17—17.78) 0.05 
PE 438 1 / 14  11 / 424 7.14 2.59 2.89 (  0.35—24.07) 0.33 
GH 438 4 / 41 8 / 397 9.76 2.02 5.26 (  1.51—18.29) 0.02 
SGA 437 3 / 42  9 / 395 7.14 2.28 3.30 (  0.86—12.69) 0.10 
PP13  ( ≤ 0.5MoM) 
Preterm+PE 438 2 / 7  25 / 431 28.57 5.80 6.50 (  1.20—35.16) 0.06 
Preterm+GH 438 2 / 10  25 / 428 20.00 5.84 4.03 (  0.81—19.99) 0.12 
Preterm 438 3 / 32  24 / 406 9.38 5.91 1.65 (  0.47—5.79) 0.44 
PE 438 2 / 14  25 / 424 14.29 5.90 2.66 (  0.56—12.54) 0.21 
GH 438 7 / 41  20 / 397 17.07 5.04 3.88 (  1.53—9.83) 0.002 
SGA 437 7 / 42  20 / 395 16.67 5.06 3.75 (  1.48—9.48) 0.003 
Preterm+PE : Delivery before 37 gestational weeks + Preeclampsia  
Preterm+GH : Delivery before 37 gestational weeks + Gestational hypertension  
Preterm : Preterm birth, delivery before 37 gestational weeks 
PE : Preeclampsia 
GH : Gestational hypertension 
SGA: birth weight less than the 10th percentile 
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Table 8. The median MoMs for biomarkers in the outcome groups 
 PAPP-A hCG Inhibine-A ADAM12 PP13 
Preterm+PE 0.33 0.57 0.73 0.89 0.65 
Preterm+GH 0.36 0.64 0.94 0.82 0.65 
Preterm 0.76 1.08 1.07 0.77 0.85 
PE 0.53 0.70 0.80 0.91 0.79 
GH 0.52 0.79 0.96 0.89 0.79 
SGA 0.62 0.85 0.88 1.03 0.83 
Preterm+PE : Delivery before 37 gestational weeks + Preeclampsia  
Preterm+GH : Delivery before 37 gestational weeks + Gestational hypertension  
Preterm : Preterm birth, delivery before 37 gestational weeks 
PE : Preeclampsia 
GH : Gestational hypertension 
SGA: birth weight less than the 10th percentiles 
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Table 9. Abnormal doppler pulsatility index in the 1st and 2nd trimester outcomes 
PI1_Per95  
N Percentage ( %)  
total yes no yes no 
Odds Ratio  
(95% CI) 
 
p 
Preterm+PE 552 1 / 5  27 / 547 20.0 4.9  4.8 (0.5—44.6) 0.23 
Preterm+GH 552 1 / 8  27 / 544 12.5 5.0  2.7 (0.3—23.0) 0.34 
Preterm 552 1 / 33  27 / 519 3.0 5.2  0.6 (0.1—4.3) 1.00 
PE 553 1 / 16  27 / 537 6.3 5.0  1.3 (0.2—9.9) 0.57 
GH 553 4 / 46  24 / 507 8.7 4.7  1.9 (0.6—5.8) 0.28 
SGA 550 6 / 46  22 / 504 13.0 4.4  3.3 (1.3—8.6) 0.01 
PI2_Per90  
Preterm+PE 487 5 / 6  51 / 481 83.3 10.6 42.2(4.8—367.9) 0.001 
Preterm+GH 487 7 / 9  49 / 478 77.8 10.3 30.6(6.2—151.6) 0.001 
Preterm 487 8 / 29  48 / 458 27.6 10.5 3.3 (1.4—7.7) 0.005 
PE 489 7 / 16  50 / 473 43.8 10.6 6.6 (2.3—18.4) 0.001 
GH 489 14 / 44  43 / 445 31.8 9.7 4.4 (2.1—8.9) 0.001 
SGA 486 11 / 42  45 / 444 26.2 10.1 3.1 (1.5—6.7) 0.002 
Preterm+PE : Delivery before 37 gestational weeks + Preeclampsia  
Preterm+GH : Delivery before 37 gestational weeks + Gestational hypertension  
Preterm : Preterm birth, delivery before 37 gestational weeks 
PE : Preeclampsia 
GH : Gestational hypertension 
SGA: birth weight less than the 10th percentiles 
PI1_per95 : mean pulsatility index ≥ 95th  percentile in the first trimester 
PI2_per90 : mean pulsatility index ≥ 90th  percentile in the second trimester 
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Table 10. Bilateral notch and diseases studied 
1. Have bilateral notch at first trimester  
N Percentage (%)  
total yes no yes no 
Odds Ratio  
(95% CI) 
 
p 
Preterm+PE 580 4 / 6  226 / 574 66.70 39.40 3.08 (0.56—16.95) 0.221 
Preterm+GH 580 6 / 9  224 / 571 66.70 39.20 3.10 (0.77—12.51) 0.166 
Preterm 580 16 / 36  214 / 544 44.40 39.30 1.23 (0.63—2.43) 0.544 
PE 581 7 / 18 223 / 563 38.90 39.60 0.97 (0.37—2.54) 0.951 
GH 581 21/ 50 209 / 531 42.00 39.40 1.12 (0.62—2.01) 0.715 
SGA 578 26 / 53  204 / 525 49.10 38.90 1.52 (0.86—2.67) 0.148 
2. Have bilateral notch at second trimester 
Preterm+PE 522 5 / 6 127 / 516 83.30 24.60 15.32 (1.77—132.32) 0.005 
Preterm+GH 522 6 / 9  126 / 513 66.70 24.60  6.14 (1.51—24.92) 0.010 
Preterm 522 11 / 31  121 / 491 35.50 24.60  1.68 (0.78—3.61) 0.178 
PE 525 8 / 18  125 / 507 44.40 24.70  2.45 (0.94—6.33) 0.058 
GH 525 21 / 49 112 / 476 42.90 23.50  2.44 (1.33—4.46) 0.003 
SGA 521 18 / 47  114 / 474 38.30 24.10  1.96 (1.05—3.66) 0.032 
3. No bilateral notch at first trimester and have bilateral notch at second trimester 
Preterm+PE 515 1 / 6  52 / 509 16.67 10.22 1.76 (0.20—15.34) 0.48 
Preterm+GH 515 1 / 9  52 / 506 11.11 10.28 1.09 (0.13—8.90) 1.00 
Preterm 515 3 / 31  50 / 484 9.68 10.33 0.93 (0.27—3.17) 1.00 
PE 516 3 / 17 50 / 499 17.65 10.02 1.92 (0.54—6.93) 0.40 
GH 516 7 / 48 46 / 468 14.58 9.83 1.57 (0.67—3.69) 0.30 
SGA 514 5 / 46  48 / 468 10.87 10.26 1.07 (0.40—2.83) 0.90 
4. Have bilateral notch at first trimester and no bilateral notch at second trimester 
Preterm+PE 515 0 / 6 120 / 509 0 23.58  0.99 (0.97—0.99) 0.34 
Preterm+GH 515 1 / 9  119 / 506 11.11 23.52  0.41 (0.05—3.28) 0.69 
Preterm 515 5 / 31  115 / 484 16.13 23.76  0.62 (0.23—1.64) 0.39 
PE 516 2 / 17  118 / 499 11.76 23.65  0.43 (0.10—1.91) 0.38 
GH 516 7 / 48 113 / 468 14.58 24.15  0.54 (0.23—1.23) 0.14 
SGA 514 10 / 46  110 / 468 21.74 23.50  0.90 (0.44—1.88) 0.78 
5. Have bilateral notch at first trimester and second trimester 
Preterm+PE 515 4 / 6  73 / 509 66.67 14.34 11.95(2.15—66.40) 0.005 
Preterm+GH 515 5 / 9  72 / 506 55.56 14.23 7.54 (1.98—28.73) 0.005 
Preterm 515 8 / 31  69 / 484 25.80 14.26 2.09 (0.90—4.87) 0.08 
PE 516 5 / 17  72 / 499 29.41 14.43 2.47 (0.85—7.22) 0.155 
GH 516 14 / 48  63 / 468 29.17 13.46 2.65 (1.35—5.21) 0.004 
SGA 514 13 / 46  64 / 468 28.26 13.68 2.49 (1.24—4.98) 0.008 
Preterm+PE : Delivery before 37 gestational weeks + Preeclampsia  
Preterm+GH : Delivery before 37 gestational weeks + Gestational hypertension  
Preterm : Preterm birth, delivery before 37 gestational weeks 
PE : Preeclampsia 
GH : Gestational hypertension 
SGA: birth weight less than the 10th percentile 
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Table 11. Mean *PI and the prevalence of the 95th percentile PI, the 90th percentile PI and 
Bilateral Notch in *normal pregnancies  
Mean PI Bilateral Notch *95th PI *90th PI 
Gestational weeks n Mean PI (95% CI) p n Percen 
tage(%) 
n Percen 
tage(%) 
n Percen 
tage (%) 
11 —11+6 95 1.56 (1.45 – 1.67) 47 48 4 4.2   
12 —12+6 268 1.44 (1.38 – 1.51) 116 70 13 4.9   
13 —13+6 144 1.27 (1.20 – 1.35) 44 43 7 4.9   
Total 507  
< 0.001 
209  24   
17 —17+6 17 0.92 (0.80 – 1.04) 7 41   1 5.9
18 —18+6 84 0.95 (0.88 – 1.00) 25 30   8 9.5
19 —19+6 180 0.91 (0.88 – 0.95) 42 22   18 10.2
20 —20+6 134 0.90 (0.85 – 0.95) 29 21   13 9.9
21 — 21+6 30 0.85 (0.79 – 0.92) 6 20   3 10.0
Total 325  
= 0.714 
109    43 
*PI: mean pulsatility index  
*Normal pregnancies: pregnancies without adverse outcomes   
*95th PI: The 95th percentile PI in first trimester 
*90th PI : The 90th percentile PI in second trimester 
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Table 12 . Area under ROC curve and the validity parameters of the predictive model   
 Area under curve 
(95%CI ) (%) 
False Positive 
Value (%) 
Sensitivity 
(%) 
Specificity 
(%) 
LR(+) p 
11 – 13+6 Gestational weeks  
Preterm+PE 94.9 (90.4—99.5) 3.0 71.4 97.0 23.8 .001 
Preterm+GH 85.2 (71.9—98.6) 8.3 60.0 91.7 7.2 .001 
Preterm 71.9 (61.3—82.6) 11.9 46.9 88.1 3.9 .001 
PE 73.0 (59.5—86.5) 9.0 57.9 91.0 6.4 .001 
GH 68.6 (59.5—86.5) 12.5 46.3 87.5 3.7 .001 
SGA 59.4 (48.9—70.0) 8.5 27.0 91.5 3.1 .058 
17 – 21+6 Gestational weeks  
Preterm+PE 97.5 (94.7—100.0) 9.9 100.0 90.1 10.1 .001 
Preterm+GH 87.4 (71.7—100.0) 4.3 77.8 95.7 18.1 .001 
Preterm 63.6 (51.4—75.9) 12.1 41.1 87.9 3.4 .001 
PE 75.0 (60.0—90.0) 9.1 60.0 90.9 6.6 .001 
GH 73.6 (63.7—83.4) 11.4 48.6 88.6 4.3 .001 
SGA 68.9 (59.4—78.4) 7.3 28.1 71.9 3.8 .001 
Preterm+PE : Delivery before 37 gestational weeks + Preeclampsia.  
(Predictors in the model: 
First trimester: PAPP-A≤0.5MoM, PP13 ≤0.5MoM, free β-hCG≤0.5MoM, BMI≥28, ethnic African-Car, chronic 
disease history and maternal age 
Second trimester: PAPP-A≤0.5MoM, PP13 ≤0.5MoM, free β-hCG≤0.5MoM, BMI≥28, ethnic African-Car, 
chronic disease history, maternal age, mean pulsatility index ≥ the 90th  percentile and bilateral notch with a 
persistent presence from first trimester to second trimester) 
Preterm+GH : Delivery before 37 gestational weeks + Gestational hypertension.  
(Predictors in the model:  
First trimester: PAPP-A≤0.5MoM, ADAM12 ≤0.5MoM, BMI≥28, ethnic African-Car, chronic disease history 
and maternal age 
Second trimester: PAPP-A≤0.5MoM, ADAM12 ≤0.5MoM, BMI≥28, ethnic African-Car, chronic disease 
history maternal age, mean pulsatility index ≥ 90 percentiles and bilateral notch with a persistent presence 
from first trimester to second trimester 
PE : Preeclampsia.  
(Predictors in the model: 
Second trimester:  PAPP-A≤0.5MoM, ethnic African-Car, BMI≥28, maternal age and mean pulsatility index ≥ 
the 90 percentile  
Preterm : Preterm birth, delivery before 37 gestational weeks.  
GH : Gestational hypertension.  
SGA: birth weight less than the 10th percentile 
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Table 13.  Predictive values of different combinations for early on-set preeclampsia (2nd trimester) 
 Area under curve 
(95%CI ) (%) 
False Positive 
Value (%) 
Sensitivity 
(%) 
Specificity 
(%) 
LR(+) p 
*A total 
combination 
97.5 (94.6 –100.0)  9.9 100 90.1 10.0 .001 
*Biomarkers 
combination 
75.5 (50.7—100.0) 11.5 66.7 88.5 5.8 .032 
*Maternal 
characteristics 
combination 
86.5 (69.5 –100.0) 9.0 83.3 91.0 9.3 .002 
Mean *PI at 17 
to 21+6 weeks 
85.9 (68.5 –100.0) 11.5 83.3 88.5 7.2 .003 
Persistent 
bilateral notch 
75.3 (53.0 –97.6) 16.1 66.7 83.9 4.1 .033 
*A total combination: PAPP-A≤0.5MoM, PP13 ≤0.5MoM, free β-hCG≤0.5MoM, BMI≥28, ethnic African-Car, 
chronic disease history, maternal age, mean pulsatility index ≥ the 90th  percentile and bilateral notch with a 
persistent presence from first trimester to second trimester 
*Biomarkers combination: PAPP-A≤0.5MoM, PP13 ≤0.5MoM, free β-hCG≤0.5MoM 
*Maternal characteristics combination: BMI≥28, ethnic African-Car, chronic disease history, maternal age 
*PI: mean pulsatility index  
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Figure 2. Different hypertensions and their preterm birth rates.  
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BMC Pregnancy Childbirth 6, 2006)) 
 
 
 67
Figure 3.  The uteroplacental blood supply 
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Figure 4.  Normal third trimester uteroplacental flow velocity waveform with high 
diastolic flow. 
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Figure 5. Diagrammatic representation of the Doppler indices and diastolic notch 
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Figure 6. Abnormal FVW with decreased diastolic flow and pronounced diastolic 
notch. 
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Figure 7. Maternal biochemical markers median tendency in first trimester 
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Figure 8. Mean PI in different gestational weeks in normal pregnancy 
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Figure 9.Combination and predictive values for early onset preeclampsia 
                 
 
 
 
1*A total combination: PAPP-A≤0.5MoM, PP13 ≤0.5MoM, free β-hCG≤0.5MoM, BMI≥28, ethnic African-Car, 
chronic disease history, maternal age, mean pulsatility index ≥ the 90th  percentile and bilateral notch with a 
persistent presence from first trimester to second trimester 
2*Biomarkers combination: PAPP-A≤0.5MoM, PP13 ≤0.5MoM, free β-hCG≤0.5MoM 
3*Maternal characteristics combination: BMI≥28, ethnic African-Car, chronic disease history, maternal age 
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Formulaires d’information et de consentement 
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1. FORMULAIRE D’INFORMATION ET DE 
CONSENTEMENT 
 
TITRE DE L’ÉTUDE : Stratégie de dépistage précoce du risque 
de prééclampsie par marqueurs sériques maternels et Doppler 
des artères utérines: Étude pilote à l’Hôpital Sainte-Justine 
 
 Chercheur principal (Hôpital Sainte-Justine): François Audibert, 
MD 
 
 Collaborateurs de l’Hôpital Sainte-Justine:  Edgard Delvin, MD  
     William Fraser, MD 
     Zhong-Cheng Luo,                      
                                                                                                  PhD 
     Lucie Morin, MD 
       Evelyne Rey, MD 
Lise Tremblay, PhD 
Françoise Rypens,     
                          MD   
 
 
 
Nous vous invitons à participer à une étude ayant pour but d’étudier 
des tests de dépistage précoce de la prééclampsie, une maladie de 
la grossesse caractérisée par l’apparition d’une hypertension 
artérielle et de protéines dans l’urine. 
 
Cette étude est financée par le Centre de Recherche de l’Hôpital 
Sainte-Justine et les Instituts de Recherche en Santé du Canada 
(IRSC). 
 
Prenez tout le temps nécessaire pour lire les lignes qui suivent. 
Pour plus d’informations, n’hésitez pas à poser des questions au 
personnel de l’étude. 
 
 
1. Pourquoi mener une telle étude? 
Les médecins responsables de cette enquête souhaiteraient vérifier la faisabilité de 
cette étude au sein de notre établissement hospitalier avant de mettre en place une 
étude clinique de grande envergure qui aura lieu dans plusieurs centres hospitaliers. 
L’étude a pour objectif général d’élaborer un test de prédiction de la prééclampsie qui 
reposera sur la combinaison de certains tests sanguins et échographiques (Doppler 
utérin) au cours de la grossesse.  Environ 2000 femmes enceintes seront recrutées pour 
participer à cette étude. 
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2. En quoi consiste ma participation à l’étude? 
Avec votre permission, le personnel de recherche pourra avoir accès à votre dossier 
médical et saisir les données cliniques concernant votre statut de grossesse, les 
traitements que vous aurez reçu et les événements qui auront eu lieu du début de votre 
grossesse jusqu’à votre accouchement. L’infirmière de recherche vous posera 
également quelques questions afin d’évaluer votre risque de prééclampsie. Votre 
participation à cette enquête implique un test sans risques pour vous ou votre bébé 
(doppler) effectué en même temps que l’échographie du 1er  trimestre qui consiste à 
mesurer le flot sanguin des artères utérines. Cette mesure sera effectuée une deuxième 
fois au 2ième  trimestre de la grossesse lors de votre échographie de routine. Ces tests 
seront combinés à une prise de sang qui déterminera le niveau dans votre sang de 
certaines protéines associées au fonctionnement placentaire. La prise de sang du 
premier trimestre sera faite en même temps que les prélèvements pour le dépistage de 
la trisomie 21 et nécessitera de prendre 4ml de sang supplémentaire (soit moins d’une 
cuillère à thé).  La deuxième prise de sang ne sera pas combinée à des tests de routine, 
nous devrons prélever 8 ml de sang soit environ 2 cuillères à thé. Ce projet représente la 
première étape d’une étude de plus grande envergure.  Cependant, dans l’éventualité 
qu’aucun support financier ne soit obtenu pour poursuivre cette étude, et qu’une partie 
des tests biochimiques ne puissent être complétés, l’investigateur s’engage à détruire 
les échantillons sanguins prélevés. 
 
3. Quels sont les bénéfices reliés à ma participation? 
Les résultats de ces tests ne seront pas utilisés avant d’avoir obtenu les conclusions de 
l’étude. En conséquence, votre participation ne modifiera pas la prise en charge de votre 
grossesse, ni la surveillance ni les traitements qui vous seront proposés, mais conduira à 
une meilleure compréhension et un meilleur dépistage de la prééclampsie. 
 
4. Quels sont les risques potentiels reliés à ma participation? 
Il n'y a aucun risque pour vous ou votre bébé lors de l’échographie et du Doppler. 
L’étude pourrait allonger la durée de votre échographie d’une durée de 5 à 10 minutes.  
Les réactions reliées aux prélèvements sanguins sont, le plus souvent, une irritation 
locale et une douleur légère.  Un petit saignement et/ou une petite contusion 
momentanée (un bleu) pourraient survenir. 
 
5. Y a-t-il d’autres options possibles? 
Si vous refusez de participer à cette étude, le dépistage du premier trimestre pour la 
trisomie 21 sera effectué comme convenu sans ajouter le doppler pour le dépistage de la 
préeclampsie. 
 
6. Comment la confidentialité est-elle assurée? 
Toutes les informations recueillies dans le cadre de ce projet de recherche seront traitées 
de façon confidentielle.  Pour ce faire, les renseignements pouvant vous identifier seront 
codés et gardés sous clés pour une période de 5 ans suivant la fin de l’étude.  À moins 
qu’il n’en soit autrement exigé par la loi, les seules personnes qui auront accès 
directement à votre dossier médical dans le cadre de l’étude sont les responsables de 
l’étude, les membres du Comité d’éthique de la recherche de l’Hôpital Sainte-Justine et 
les inspecteurs des organismes de réglementation gouvernementale. 
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Par ailleurs, les résultats de cette étude pourront être publiés ou communiqués dans un 
congrès scientifique mais aucune information pouvant vous identifier ne sera alors 
dévoilée. 
 
7. Pouvez-vous refuser de faire partie de cette étude? 
Votre participation à cette étude se fait sur une base entièrement volontaire. Vous pouvez 
choisir de ne pas participer à l’étude ou vous en retirer à tout moment sans justification de 
votre part. Votre refus de participer ou votre décision de vous retirer n’affectera d’aucune 
façon la qualité des soins que vous recevrez au cours de votre grossesse ou durant et 
après votre accouchement.  
 
8.  Communication des résultats  
 
Aucun résultats personnel des tests de recherche ne vous sera communiqué mis à part 
les résultats lié au dépistage de la trisomie 21. 
 
9. Responsabilité des chercheur(e)s 
En signant ce formulaire de consentement, vous ne renoncez à aucun de vos droits 
prévus par la loi. De plus, vous ne libérez pas les investigateurs de leur responsabilité 
légale et professionnelle advenant une situation qui vous causerait préjudice.  
 
10. Qui devez-vous contacter si vous avez des questions? 
Pour toute question concernant l’étude ou pour tout dommage que vous subiriez en lien 
avec l’enquête, veuillez contacter le médecin, Dr François Audibert qui est responsable 
de cette étude à l’hôpital Sainte-Justine, en lui téléphonant au (514) 345-4706.  
 
En tout temps vous pouvez contacter l’infirmière de recherche : Valérie Tremblay au 
(514) 345-4931 poste 6827. 
 
Pour toute question concernant vos droits en tant que participante à une étude, 
vous pouvez contacter la conseillière à la clientèle de l’Hôpital Sainte-Justine au 
(514) 345-4749. 
 
Il est important de bien comprendre ce qui suit avant de signer ce 
document. Vous recevrez une copie signée de ce formulaire de 
consentement . 
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Consentement 
 
Participante 
J’ai lu et compris ce formulaire de consentement. J’ai pu discuter avec le(la) 
professionnel(le) de la santé qui m’a expliqué le but de l’étude ainsi que les 
risques et bénéfices qui lui sont associés. On a répondu à toutes mes questions. 
J’accepte de participer volontairement et librement à cette étude et j’autorise 
l’accès à mon dossier médical. 
 
 
          
Nom de la participante (lettres moulées) 
 
         __________ 
Signature de la participante                                                      Date 
 
 
 
 
Investigateur (ou personne déléguée) 
Le projet de recherche a été décrit à la participante ainsi que les modalités de la 
participation. Un membre de l’équipe de recherche (chercheur ou infirmière de 
recherche) a répondu ses  questions et lui a expliqué que la participation au 
projet de recherche est libre et volontaire. L’équipe de recherche s’engage à 
respecter ce qui a été convenu dans le formulaire de consentement.  
 
          
Nom de l’investigateur (lettres moulées) 
 
             
Signature                                          Date  
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